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Acute myelogenous leukemia (AML) is caused by successive mutations acquired in 
hematopoietic progenitor cells that lead to the overpopulation of the bone marrow and peripheral 
blood by immature myeloid cells. The overall survival rate with current therapy is 25%, which 
decreases steadily with patient age. While numerous genetic alterations occur in AML, mutations 
to the FMS-like tyrosine kinase 3 (FLT3) are the most common, occurring in 30% of patients. 
Two types of FLT3 mutations occur in AML: internal tandem duplications (ITDs) and tyrosine 
kinase domain point mutations. FLT3 mutations drive AML pathogenesis and numerous small 
molecule kinase inhibitors have been designed as therapeutics for FLT3-mutated AML.  
However, these FLT3 inhibitors have had limited clinical success owing to lack of potency in 
vivo, toxicity, or short duration of response due to the development of resistance. 
Constitutively active FLT3 links to multiple downstream tyrosine kinases that are critical 
for AML cell survival and proliferation. Gene silencing studies have shown that several of these 
FLT3-associated kinases are individually crucial for FLT3 oncogenic potential, including SYK, 
FES, and the myeloid Src-family kinase, HCK. These previous observations raised the 
hypothesis that a small molecule inhibitor with a selectivity profile targeting FLT3 plus these 
associated kinases may be a potent AML drug lead with reduced propensity for acquired 
resistance.  To test this hypothesis, we screened a library of N-phenylbenzamide compounds and 
identified a compound with three-digit nanomolar activity against each of these AML-associated 
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kinases in vitro.  Remarkably, this compound (TL02-59) inhibited FLT3-ITD+ cell growth in the 
picomolar range.  Furthermore, TL02-59 demonstrated efficacy against primary AML bone 
marrow samples and a mouse xenograft model of AML.  To explore the full range of targets for 
TL02-59, we performed a KINOMEscan assay and determined the expression of the TL02-59 
target kinases in primary AML bone marrow samples. We discovered that while myeloid Src-
family kinases HCK, LYN and FGR are critical to TL02-59 efficacy, inhibition of SYK, FES 
and the Ser/Thr kinases p38α and TAOK3 also plays a role.  Future work will explore the 
advantages of this potent, multi-targeted kinase inhibitor in combating acquired resistance in 
AML.    
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1.0 INTRODUCTION 
1.1 ACUTE MYELOID LEUKEMIA 
It is most commonly believed that the first description of a patient with leukemia was made by 
Alfred Velpeau, a surgeon in Paris at the time. In 1827, he described a patient with swelling of 
the “abdomen, fever, and weakness” (1). After this patient’s death Velpeau discovered an 
enlarged liver and spleen, as well as “blood like gruel” (2).  It was not until 1845 that blood from 
a leukemia patient was microscopically examined for the first time, by John Hughes Bennett. He 
determined that the patient had an increase in the number of “colorless corpuscles” in the blood 
(3).   The word “leukemia” was coined by Rudolf Virchow just two years later, in 1847, to 
describe a disease that filled the blood vessels with a “greenish-yellow-white substance that 
looked like pus” (4).  Numerous other breakthrough discoveries, including establishing that 
leukemia originates in the bone marrow (5), distinguishing between chronic and acute forms of 
leukemia (6), and separating myeloid versus lymphatic forms (7) were seminal in beginning the 
journey to our modern, molecular, understanding of acute myeloid leukemia. 
1.1.1 The Origins of Acute Myeloid Leukemia 
Numerous lines of evidence have indicated that leukemia arises through a multi-step 
transformation process beginning with an initiator mutation in a hematopoietic stem cell (HSC), 
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which ultimately gives rise to a leukemic stem cell (LSC) and eventually the overt disease that is 
seen clinically. 
1.1.1.1   The Multi-Step Model of AML development  The theory that AML develops through 
a multi-step process was originally proposed by Gilliland and Griffin (8).  In this paper they 
separated common AML mutations as either class I or class II, with class I mutations 
conferring a proliferative or survival advantage and class II mutations impairing 
differentiation.  Under these assumptions class I mutations are mutations such as activated 
receptor tyrosine kinases or RAS mutations and class II mutations are exemplified by fusion 
proteins containing transcription factors.  Significant direct and indirect evidence supports this 
broad-based separation of mutation types.  Under this theory, knocking-in an AML 
associated mutation (class I or class II) to mouse hematopoietic cells should not cause 
overt AML, as neither mutation alone is enough to cause disease.  In fact, this is what 
has been documented with several class I and class II mutations (9-15).  For example, when 
FMS-like tyrosine kinase receptor III (FLT3) containing an internal tandem duplication 
(ITD), a class I mutation, was knocked into mice, a fatal myeloproliferative disorder, but not 
overt AML was the result, with a median survival time of 10 months (16).  However, when the 
FLT3-ITD knock-in was combined with a NUP98-HoxD13 fusion knock-in, a class II 
mutation, 100% of the mice developed fulminant AML with a mean survival of 95 days 
(17).  Another example, using retroviral gene transfer, demonstrated that the addition of 
MLL-SEPT6, a class II mutation, to hematopoietic stem cells (HSCs) induced a lethal 
myeloproliferative disease with a long latency but never induced AML.  However, with the co-
expression of a class I mutation, FLT3-ITD, the mice developed AML with complete 
penetrance (18).  These studies provide evidence that at least two mutations are needed for 
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the clinical development of AML.  Further indirect evidence from human patients also supports a 
two-step model of AML development.  FLT3 mutations and RAS mutations, both class I 
mutations, are rarely identified in the same patient but FLT3 mutations commonly occur 
together with gene fusions that disrupt normal differentiation (19-24).  More recent genome-
wide sequencing studies have discovered novel mutations in AML that do not fit neatly into 
either the class I or class II mutation families; such as mutations in regulators of DNA 
methylation and histone modifications (25).  These mutations occur in combination with 
both class I and class II mutations, but tend to be mutually exclusive with mutations in other 
epigenetic modifiers.  This suggests a novel class of mutations that potentially work 
synergistically with the class I and class II mutations to induce AML (26).   
1.1.1.2  The Leukemic Stem Cell  The cancer stem cell (CSC) theory, first proposed in 1976, 
says that most cancers arise from a single cell that through genomic instability gives rise to the 
later stage tumors seen in the clinic (27).  This theory was further expounded upon in two 
studies that provided evidence for the necessary characteristic of a CSC population; self-
renewal and quiescent phenotype (28, 29).  These early theories were based on studies in 
AML showing that only a small fraction of cells are capable of incorporating 3H-thymidine, 
suggesting that only a small fraction of the bulk tumor cell population is actually moving 
through the cell cycle (30, 31).  Subsequent studies, exploring AML cell growth in 
methylcellulose, further supported the CSC theory (32, 33). These studies again discovered that 
only a fraction of bulk tumor cells could expand in methylcellulose, and thus only this 
population of tumor cells is capable of repopulating the tumor.  While a number of studies 
would further characterize the leukemic stem cell (LSC) and the likelihood of its existence 
(34-36), it was not until the mid-1990s that the first evidence of a LSC capable of repopulating 
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an in vivo xenograft model was discovered. These two seminal studies demonstrated the ability 
of human CD34+CD38- peripheral blood or bone marrow AML cells to repopulate the tumor in 
a naïve recipient mouse (37, 38).  Both studies discovered that the transplanted LSCs 
reproduced AML in mice that closely recapitulated the clinical characteristics seen in the human 
patient.  In the twenty years since the LSC was identified, numerous studies have further 
characterized the LSC as sharing many of the same traits of normal HSCs, including their ability 
to self-renew (39-41) and their quiescent nature (42, 43).  Additionally, more recent studies 
indicate that LSCs share a niche with HSCs, providing the microenvironment necessary for 
stem cell survival (44).  The investigation of LSCs has become extremely important as one 
study discovered that high leukemic stem cell frequency at diagnosis predicts a poor 
prognosis (45).        
 Combining LSCs with the two-hit model discussed in the previous section, it is most 
commonly thought that the first mutation in AML occurs in an HSC, leading to a pre-
leukemia stem cell and eventually a second mutation leads to an LSC (Figure 1) (37, 41).  
However, several studies have discovered that restricted progenitor cells are capable of 
receiving an initiator mutation that reactivates self-renewal (46-48).  This cell is then capable 
of obtaining a second mutation to be transformed into an LSC.  The quiescent nature of 
LSCs leads most researchers to believe that an intermediate cell exists before the development 
of leukemic blasts (41, 49, 50). This cell is a leukemic progenitor cell with significantly 
increased ability to proliferate into leukemic blasts and a limited ability to self-renew.  The blast 
population contains no potential to self-renew but is able to proliferate excessively.
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Figure 1: The two step model of AML development 
 Leukemia develops through a two-step mutation process. Normally original mutations occur in the hematopoietic 
stem cells and then a secondary mutation leads to the development of an LSC fully capable of self-renewal and 
proliferation into leukemic blasts. However, it is possible for restricted progenitor cells to acquire the initiating 
mutation and then a secondary mutation can occur in the same cell leading to an LSC.  Current therapy targets the 
AML blasts but fails at eliminating the leukemic stem cells.  Adapted from Roboz et. al. (49).     
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1.1.2  Common Mutations Occurring in AML 
Two large genome-wide sequencing studies of AML discovered that it has one of the lowest 
median mutation frequencies of all adult cancers (Figure 2) (51, 52).  However, significant 
patient to patient variation existed in both studies.  Further sequencing studies have identified a 
core set of commonly mutated genes in AML. The following sections will briefly discuss each of 
them and their role in AML pathogenesis.         
 
Figure 2: Common mutations in AML. 
AML has many commonly occurring mutations and most patients carry more mutations from a number of different 
protein families.  This depicts an overview of how common mutations the frequency of mutations in each family and 
some of the most common mutations from that family.  Mutation data from The Cancer Genome Atlas (51) and 
figure adapted from Chen et. al. (53) 
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1.1.2.1  Signaling Pathway Mutations  According to The Cancer Genome Atlas, signaling 
pathway proteins are the most commonly mutated genes in AML (51).  Mutations most 
commonly occur in the, FLT3, c-KIT, RAS, and to a lesser extent Janus Kinase 2 (JAK2) 
genes.  FLT3 is the most commonly mutated gene in AML, and will be discussed in great 
detail in the following sections. 
 c-KIT is a receptor tyrosine kinase that under normal circumstances responds to its 
ligand, stem cell factor (SCF), to regulate the growth and survival of hematopoietic stem cells 
(54, 55).  When mutated in approximately 3-5% of AML cases (56), most commonly by point 
mutations in the activation loop at D816, c-KIT becomes constitutively active. Oncogenic c-
KIT induces activation of the phosphoinositide 3-kinase (PI3K) pathway (57) and activation 
of signal transducer and activator of transcription 3 (STAT3) leading to upregulation of STAT3 
target genes, including, B-cell lymphoma-extra large (BCL-xL) and c-MYC (58).  c-KIT 
mutations are most commonly found in conjunction with core binding factor (CBF) 
mutations (59) and runt-related transcription factor 1 (RUNX1) mutations (60).  It is clear 
from the literature that the addition of a c-KIT mutation has a negative prognostic impact on 
CBF- and RUNX1-mutated AML (60-64). 
   RAS mutations, almost exclusively at codons 12 and 13, occur in approximately 20% of 
AML patients and lead to a constitutively active, GTP-bound form of RAS which activates its 
downstream effectors such as RAF and MEK (65).  RAS mutations most commonly occur 
in AML with inv(16) [CBF fusions to Myosin, Heavy Chain 11 (MYH11)] and AML with 
inv(3), which leads to the overexpression of the EVI1 transcription factor through the 
repositioning of a GATA2 enhancer upstream of its promoter (59, 61, 66).  Overall, the 
prognostic impact of RAS mutations in AML remains unclear as published studies show RAS 
mutations lead to favorable, unfavorable, or neutral outcomes (67-70).    
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JAK2, a non-receptor tyrosine kinase normally activated downstream of cytokine 
receptors (i.e. Interleukin Receptor 3 (IL3R)), is mutated in 1-3% of AML patients (71-73).  
Mutations occur almost exclusively as phenylalanine substitutions at position V617 in the kinase 
domain, leading to constitutive activation of the kinase and its downstream effectors; STAT5 and 
PI3K/AKT (74).  JAK2 mutations do not occur with any particular cytogenetic aberration but 
they are associated with less differentiated AML (72).  Few studies have explored the prognostic 
impact of JAK2 mutations; however, one study discovered that upregulation of JAK2 
phosphorylation was a predictor of worse response to chemotherapy (75).   
1.1.2.2 Mutations in DNA Methylation Proteins  Mutations affecting the process of DNA 
methylation are among the most recent commonly occurring mutations identified in 
AML.  They are characterized by mutations in tet methylcytosine dioxygenase 2 
(TET2), Isocitrate Dehydrogenase 1/2 (IDH1/2), and DNA Methyl Transferase 3a (DNMT3A). 
TET2 loss of function mutations occur in 7-23% of AML cases (76).  TET2 loss disrupts 
normal hematopoietic differentiation and provides a proliferative advantage to these cells.  
Furthermore, these mutations are thought to be early events in progenitor cells and most 
commonly are identified at diagnosis and relapse. TET2 mutations are most 
commonly discovered in cytogenetically normal AML (CN-AML) (77).  The prognostic 
impact of TET2 mutations is still under investigation. However, it was recently discovered that 
TET2 mutations confer shorter event-free survival and shorter disease-free survival in CN-AML 
(78).   
IDH1/2 are NAD+-dependent enzymes responsible for converting isocitrate 
dehydrogenase to  α-ketoglutarate (79, 80).  Gain of function mutations occur exclusively in one 
of three arginines (IDH1 R132, IDH2 R172, IDH2 R140) that allow these enzymes to convert 
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α-ketoglutarate to 2-hydroxyglutarate (2-HG) (81, 82).  Subsequent studies revealed that IDH 1/2 
mutations are mutually exclusive with TET2 mutations and AML driven by either of these 
mutations has a similar global promoter hypermethylation pattern.  From these previous studies, 
it was determined that 2-HG is capable of inhibiting TET2 enzymatic activity (77, 83).  IDH 1/2 
mutations induce expression markers of immature cells, with a phenotype nearly identical to 
TET2 mutated AML.  Mutations have been identified in approximately 10-20% of AML cases, 
most commonly with mutated NPM1 but without FLT3-ITD (84).  Both IDH1/2 mutations 
confer a poor prognosis (85-87).  
DNMT3A mutations occur in approximately 15-25% of AML patients, most commonly in 
conjunction with FLT3 and NPM1 mutations (88).  DNMT3A mutations are either single 
nucleotide changes at R882 or premature truncation by nonsense or frameshift mutations (89).  
Normally DNMT3A is responsible for the methylation of CpG motifs in DNA but when mutated 
it loses enzymatic activity leading to hypomethylation of certain genes. Additionally, since 
dimerization is essential for DNMT3A function, it is plausible that the mutations are dominant-
negative. The role of mutated DNMT3A is not completely understood; however, global 
methylation data suggest that loss of DNMT3A increases expression of HOX genes through 
promoter hypomethylation (89).  Numerous studies have identified the HOX genes as crucial for 
AML development (90).  The prognostic impact of DNMT3A mutations is not completely 
understood, but in a particular subgroup of CN-AML patients (NPM1wild type/FLT3wild type) 
DNMT3A mutations confer a significantly worse prognosis (91).   
1.1.2.3 Mutations in Chromatin Modifying Proteins  The mixed lineage leukemia (MLL) 
mutations or fusions were among the first mutations discovered in AML. More recent 
work has described mutations in other chromatin modifying proteins such as Additional Sex
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Combs Like 1 (ASXL1) and Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit 
(EZH2).  
Over 50 different MLL fusion partners have been described in AML but just five fusion 
partners account for 80% of all MLL-bearing leukemias (92, 93). In all fusion proteins, MLL 
loses its intrinsic H3K4 methyltransferase activity (94) but frequently gains H3K79 
methyltransferase activity through an abnormal association with DOTL1 (95). In addition to 
fusions, MLL mutations also occur as partial tandem duplications (PTDs); in-frame duplication 
of a portion of the MLL protein (96, 97).  MLL-PTDs do not perturb the intrinsic 
methyltransferase activity of MLL but instead increase hematopoietic progenitors in vivo 
through the induction of HOX genes (98). MLL mutations occur in approximately 5-10% of all 
AML cases and are particularly common in infant acute leukemias and secondary leukemia 
developed after topoisomerase II inhibitor treatment (99).  All MLL mutations confer a poor 
prognosis (100, 101).   
ASXL1 mutations occur in approximately 10-15% of AML cases and are highly enriched 
for secondary AML that developed from a myeloproliferative disease (102, 103). Somatic 
nonsense, missense, frameshift and point mutations have been discovered in ASXL1, with 
frameshifts being the most common (104).  How ASXL1 mutations contribute to leukemogenesis 
is poorly understood. However, ASXL1, is the DNA-binding component of the polycomb 
repressor complex 2 (PRC2) which functions to enact H3K27 trimethylation marks (105).  Since 
ASXL1 mutations typically reduce expression of ASXL1, it is postulated that loss of ASXL1 
inhibits recruitment of PRC2 to proper loci in DNA, leading to a loss of H3K27 trimethylation. 
ASXL1 mutations are early events and the association with disease outcome is still being debated 
(106-108).   
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 EZH2 is the methyltransferase enzyme in the PRC2 complex responsible for H3K27 
methylation (109).  Loss of function mutations in EZH2 decrease global H3K27 methylation 
(110). Loss of H3K27 methylation potentially causes the aberrant expression of genes critical for 
leukemogenesis.  EZH2 is mutated in approximately 1-2% of AML patients and no prognostic 
relevance has been discovered thus far (111).     
1.1.2.4  Nucleophosmin Mutations  Nucleophosmin (NPM1) is mutated in approximately 
25-30% of AML patients with enrichment for CN-AML and AML that contains FLT3-ITD 
mutations (112).  NPM1 normally shuttles between the nucleus and cytoplasm (113), where 
it regulates protein aggregation, cell cycle progression, and the ARF-TP53 tumor suppressor 
pathway (114-116).  Most AML- associated NPM1 mutations cause a frameshift in the C-
terminal region of the protein, causing the addition of a nuclear export signal and loss of a 
nuclear localization signal (117).  Ultimately, this results in abnormal cytoplasmic-only 
localization of NPM1.  The exact role of NPM1 in leukemogenesis is unclear but it 
is associated with the upregulation of stem cells maintenance genes (118).  In the absence of 
FLT3-ITD mutations, NPM1 mutations are a good prognostic indicator, with a five-year 
survival probability of approximately 60% (119-121).
1.1.2.5  Transcription Factor Mutations  Transcription factors are essential for the 
differentiation of hematopoietic cells so not surprisingly; transcription factor mutations are 
common in AML.  Here I will discuss mutations to runt related transcription factor 1 (RUNX1), 
CCAAT/Enhancer Binding Protein alpha (CEBPA), and the retinoic acid receptor alpha (RARα).    
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RUNX1 is the DNA-binding portion of CBF which is intricately involved in the 
transcriptional programs of hematopoietic differentiation (122). Thus, loss of RUNX1 or 
impairment of its function prevents differentiation. Chimeric RUNX1 fusion proteins resulting 
from chromosomal translocations occur in approximately 10-15% of all AML cases (123).  
RUNX1 fusion proteins are associated with undifferentiated AML morphologies and commonly 
occur with trisomy 21 and trisomy 13 (124, 125).  Lower complete response rates and an overall 
worse prognosis are associated with RUNX1 fusions (126, 127). 
The CEBPA gene encodes a leucine zipper transcription factor critical for granulocytic 
differentiation (128-130).  CEBPA mutations occur in approximately 10-20% of AML patients 
and occur in parallel with FLT3-ITD and NPM1 mutations (131).  Three different varieties of 
mutations occur in CEBPA and typically CEBPA mutations are biallelic.  Nonsense N-terminal 
mutations create a dominant-negative truncated isoform that prevents the expression of 
granulocyte differentiation genes (132, 133).  C-terminal point mutations reduce DNA binding 
and dimerization affinity (134, 135).  Finally, other studies identified DNA hypermethylation at 
the CEBPA promoter, eliminating its expression (136).  Generally, CEBPA mutations are a good 
prognostic marker and lead to a favorable treatment response (137, 138). 
RARα is a vitamin A-responsive nuclear receptor that requires heterodimerization to the 
RXR nuclear receptor for its function.  RARα is essential for myeloid differentiation in the 
granulocyte/monocyte lineages (139) and loss of RARα results in a differentiation block at the 
promyelocyte stage (140).  Fusion of RARα to the promyelocytic leukemia gene (PML) from the 
t(15;17) chromosomal translocation, is the most common cause of acute promyelocytic leukemia 
(APL) (141, 142).  The PML-RARα fusion protein acts like wild-type RARα which has lost the 
ability to respond to vitamin A (143).  APL cases account for 5-10% of all AML patients and has 
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an excellent prognosis (144).  Treatment with all-trans retinoic acid (ATRA) and arsenic-trioxide 
(ATO) induces the differentiation of PML-RARα expressing cells and gives APL a cure rate of 
approximately 75-85% (145, 146).     
1.1.2.6 Tumor Suppressor Mutations  TP53 mutations are extremely common in solid tumors 
but only occur in approximately 10% of AML cases (147).  Inactivating mutations or loss 
of a TP53 allele through imbalanced translocation results in impairment of apoptosis, 
genome instability, and deficiency in cell cycle arrest (148-150).  Commonly, TP53 mutations 
are biallelic (151, 152), and are most common in the elderly and patients with complex 
karyotype AML (153). Poor prognosis and short survival time are typical in patients with TP53 
mutations (154).         
Wilms Tumor 1 (WT1) encodes a zinc-finger DNA binding protein that is mutated in 
5-10% of AML cases (155).  Depending on the cellular context, WT1 can be a tumor suppressor 
or an oncogene obscuring its exact role in leukemogenesis (156).  However, two recent 
studies suggest that loss of WT1 function causes a block in hematopoietic differentiation 
(157, 158).  While the exact prognostic impact of WT1 mutation remains uncertain, several 
small studies suggest it promotes induction failure and shorter overall survival (155).   
1.1.3 Classification of AML 
Three separate methods are used in the clinical classification of AML; the French-American-
British (FAB) classification system, the World Health Organization (WHO) classification 
system, and the European LeukemiaNet Standardized System (ELN).  Each is described briefly 
in the following sections. 
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1.1.3.1 French-American-British Classification  Originally published in 1976, the FAB 
classification system is the oldest method of classifying AML patients (159). Classification 
is based entirely on morphological appearances of a Romanowsky-stained bone marrow 
film.  Additionally, cytochemical stains for myeloperoxidase and non-specific esterase are used 
to distinguish between certain subgroups. At its advent, the FAB system classified AML into 
six subcategories, M1 through M6 (Table 1).  An update to the system in 1985 added the M7 
subcategory (160, 161) and a final update in 1991 added an M0 category (162).  Furthermore, 
the FAB classification system set the arbitrary cutoff for AML at >30% blasts in the bone 
marrow.  Anything less than 30% blasts is considered to be a myelodysplastic syndrome (MDS) 
as opposed to frank leukemia.  
The FAB classification system allowed clinicians to determine the prognosis of each 
subtype. Additionally, with a universal classifications system, clinical trial results could be 
compared more easily. However, it is obvious with the luxury of hindsight that the FAB 
classification has its limitations.  First, despite the significant histological detail described for 
each subtype, reproducibility of subtype classification between researchers/clinicians varied 
significantly (163, 164). Additionally, immunological and genetic studies began to describe 
subtypes of AML that were not distinguishable in the FAB system.  Furthermore, accumulating 
evidence suggested that the FAB subtypes, except M3 with is caused by the PML-RARα fusion 
95% of the time (165), did not equate to a particular cytogenetic abnormality, even though some 
mutations/ translocations are more common in certain subtypes (166).  Since response to therapy 
is largely determined by cytogenetic abnormalities, the FAB system had limited prognostic 
value, beyond outcomes in the M3 subtype being most favorable, and outcomes in the M1 and 
M7 subtypes being least favorable (167).  The final issue with the FAB classifications system is 
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how it separates MDS from AML.  The 30% cutoff is arbitrary and some patients are likely 
misclassified (168).  Additionally, MDS cases often develop into AML with specific alterations, 
and no subgroup existed for this type of AML (169).  These issues combined with novel genetic 
data prompted the development of the WHO classification system.   
 
FAB Subtype Name 
M0 Undifferentiated acute myeloblastic leukemia 
M1 Acute myeloblastic leukemia with minimal maturation 
M2 Acute myeloblastic leukemia with maturation 
M3 Acute promyelocytic leukemia 
M4 Acute myelomonocytic leukemia 
M5 Acute monocytic leukemia 
M6 Acute erythroid leukemia 
M7 Acute megakaryoblastic leukemia 
 
Table 1: The FAB Classification System 
The FAB classification system was the first system used to classify AML and was based entirely on morphological 
appearance. The eight subgroups are shown in the table and they are divided on extent of differentiation and cell of 
origin.  
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1.1.3.2 The World Health Organization (WHO) Classification  The WHO classification 
system was originally published in 2001 (170), updated in 2008 (171) and the further refined 
in 2016 (172).  At its advent, this AML classification system incorporated immunophenotyping 
and genetic approaches into the already existing morphological system grounded in the FAB 
approach.  In the 2016 edition, AML is divided into four major categories; AML with recurrent 
genetic abnormalities, AML with myelodysplasia-related changes, therapy-related myeloid 
neoplasms, and AML not otherwise specified (NOS) (Table 2).  Additionally, the WHO 
classification lowered the blast percentage in the bone marrow necessary for diagnosis of AML 
to 20%.  Furthermore, it allowed for cases that carry particular genetic translocations [i.e. 
t(15;17)] to be diagnosed as AML regardless of the bone marrow blast percentage.   
The WHO classification system is an improvement on the FAB system because it 
incorporates many recurring cytogenetic abnormalities linked to patient outcome into its 
diagnosis criteria.  Additionally, it adds separate categories for AML caused by previous therapy 
and AML developing from a myelodysplastic syndrome as these two types of AML carry a 
particularly poor prognosis. However, current estimates suggest that only about 50% of AML 
patients can be classified under the first three categories of the WHO classification system (173).  
This will likely change as novel genetic abnormalities are discovered and validated as 
prognostically significant in AML.  Additionally, further refinement is needed in the AML NOS 
category because it only uses morphological characteristics to categorize patients, similar to the 
FAB system, and has little prognostic value (174).  Essentially, every AML NOS subgroup has 
the same outcome.  Finally, the WHO classification system fails to incorporate many genetic 
mutations with prognostic significance, such as the FLT3-ITD mutation which is present in more 
than 20% of AML cases.  In the most recent revision, mutations in NPM1 and CEBPA were 
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added as recurrent abnormalities because they have prognostic significance in CN-AML.  
However, it is difficult to foresee how this classification system will incorporate genetic 
mutations with prognostic significance in multiple cytogenetically mutated AML backgrounds.
   
AML with recurrent genetic abnormalities 
 AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1
 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11
 APL with PML-RARA
 AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A
 AML with t(6;9)(p23;q34.1);DEK-NUP214
 AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
 AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1
 Provisional entity: AML with BCR-ABL1
 AML with mutated NPM1
 AML with biallelic mutations of CEBPA
 Provisional entity: AML with mutated RUNX1
AML with myelodysplasia-related changes 
Therapy related myeloid neoplasms 
AML, NOS 
 AML with minimal differentiation
 AML without maturation
 AML with maturation
 Acute myelomonocytic leukemia
 Acute monoblastic/monocytic leukemia
 Pure erythroid leukemia
 Acute megakaryoblastic leukemia
 Acute basophilic leukemia
 Acute panmyelosis with myelofibrosis
Table 2: The WHO Classification System. 
The WHO classification system uses cytogenetic and genetic data to classify patients.  Any patient not classified 
with a recurrent genetic abnormality, myelodysplastic related change, or therapy related change falls into the AML, 
NOS category.  This category still relies on morphological information to sub-classify patients.   NOS: Not 
otherwise specified     
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1.1.3.3 European LeukemiaNet (ELN) Classification  The ELN was conceived because of 
the need to stratify patients based on their prognostic outcome (175).  Additionally, the 
ELN allows for the incorporation of genetic mutations with prognostic impact that occur in 
multiple cytogenetic backgrounds.  The ELN classifies patients into four main outcome 
categories; Favorable, Intermediate-I, Intermediate-II, and Adverse (Table 3).   
Numerous studies tested the prognostic significance of the ELN classification system and 
discovered significantly different outcomes in the four groups, even when patients are subdivided
Table 3: The ELN Classification System. 
The ELN was designed to classify patients based on clinical outcome.  It allows for the design of treatment 
strategies based on those who are most likely to respond.  Studies have determined that these groups have prognostic 
significance in both younger and older patient groups.     
Genetic Risk Group Subset 
Favorable 
 t(8;21)(q22;q22); RUNX1-RUNX1T1
 inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
 Mutated NPM1without FLT3-ITD (normal karyotype)
 Mutated CEBPA (normal karyotype)
Intermediate-I 
 Mutated NPM1 and FLT3-ITD (normal karyotype)
 Wild-type NPM1 and FLT3-ITD (normal karyotype)
 Wild-type NPM1 without FLT3-ITD (normal karyotype)
Intermediate-II 
 t(9;11)(p22;q23); MLLT3-MLL
 Any cytogenetics not classified as favorable or adverse
Adverse 
 inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
 t(6;9)(p23;q34); DEK-NUP214
 t(v;11)(v;q23); MLL rearranged
 Monosomy 5 or del(5q); monosomy 7; abnormal 17p;
complex karyotype (≥ 3 abnormalities)
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by age (176, 177).  One major improvement with this system is the ability to separate the CN-
AML patients based on genetic mutations.  CN-AML accounts for approximately 40-50% of 
all AML patients and this group is extremely heterogeneous for genetic mutations and 
outcomes (178).  The ELN uses NPM1, CEBPA, and FLT3-ITD mutations to stratify this group 
into both the Favorable and Intermediate-I categories, identifying differences in prognosis 
with in the CN-AML patients.  Another unique feature of this system is how easily it can be 
updated to allow for the addition of novel genetic mutations with prognostic significance.  
In fact, a number of studies have already suggested that adding other genetic mutations 
into the ELN further refines the ELN classification system (77, 107).    
1.1.4 Clinical Course of AML 
Even though AML accounts for only 1.2% of all cancers, it is the most common hematologic 
malignancy in adults with a median onset age of 67 years (179).  It is estimated that in 2016 
approximately 20,000 people will be diagnosed with AML and about 10,500 will die from the 
disease.   
1.1.4.1 Risk Factors  The majority of AML cases are ‘de novo AML’ meaning that there is 
no determinable cause.  However, a few risk factors for AML development have been 
identified.  The biggest risk factor for the development of AML is age (180).  While AML does 
occur in children and young adults under the age of 25, the incidence rate rises exponentially 
with increasing age.  Generally, the older a patient is when diagnosed with AML, the worse the 
prognosis (181).     
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 Several genetic mutations have been linked to a predisposition for developing AML.  
Studies have identified rare inherited mutations in RUNX1, CEBPA, or GATA2 in infants, 
typically under a year old, who develop AML (182, 183). Additionally, several congenital 
diseases that affect tumor suppressors or DNA repair proteins (i.e. Li-Fraumeni syndrome or 
Fanconi anemia) carry a significantly increased risk of developing AML due to the genomic 
instability associated with these diseases (184, 185).  Finally, diseases caused by abnormal 
chromosome number have an increased risk of developing AML.  For example, people with 
Down syndrome, which is caused by an extra copy of chromosome 21 (trisomy 21), have an  
increased risk of developing acute megakaryoblastic leukemia, a less common subtype of AML 
typically caused by GATA1 mutations (186).  
 The category of ‘secondary leukemia’ comprises AML patients whose leukemia 
developed because of prior exposure to cytotoxic agents or through the continued progression of 
another disease.  A large percentage of secondary leukemia patients are considered to have 
treatment-related AML. Generally, treatment-related AML is the consequence of prior treatment 
with alkylating agents or topoisomerase II inhibitors for other cancers.  Because patients 
commonly receive combination therapy, it is difficult to ascertain the causative agent.  Treatment 
with alkylating agents is associated with chromosome 5 and 7 abnormalities (187), while 
treatment with topoisomerase II inhibitors leads to a higher incidence of MLL rearrangements 
(188).  Treatment-related AML has an inferior prognosis with overall survival rates under 10% 
(189).  A very small percentage of patients presenting with secondary leukemia developed it 
through exposure to environmental carcinogens, most commonly ionizing radiation and benzene 
(190, 191).  The progression of myelodysplastic syndromes (MDS) accounts for the final portion 
of secondary leukemia.  These AML patients originally develop MDS (i.e. polycythemia vera or 
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idiopathic myelofibrosis) which then evolves into AML (192).  Evolution of MDS accounts for 
3-4% of all AML cases and as with the therapy-related AML, patients developing AML from
MDS have a significantly worse prognosis.  
1.1.4.2 Clinical Manifestations  The clinical manifestations of AML develop quickly, 
occurring over a few weeks to a few months as most (193).  The most common symptom, 
anemia, results from the loss of normal bone marrow function, resulting in fatigue, pallor 
and headache (184).  Additionally, patients tend to bruise easily and have evidence of 
bleeding, commonly noticed as bleeding gums (192).  The lack of functioning bone marrow 
depletes the immune system and AML patients often deal with recurring or severe infections 
(184).  Finally, in rare cases leukemic blasts will infiltrate the skin and lead to ‘leukemic cutis’, 
a rash that occurs with raised bumps (192).   
In the laboratory, almost all patients present with granulocytopenia even though 
peripheral white blood cell counts can be highly variable (192).  Approximately 25% of patients 
have high white blood cell counts (>50,000 cells/μL), 50% have white blood cell counts between 
5,000 and 50,000 cells/μL, and the last 25% have low white blood cell counts (<5,000 cells/μL) 
(184). Additionally, as mentioned above, patients often present with anemia and generally are 
thrombocytopenic.  While the peripheral blood can provide crucial information for the diagnosis 
of AML, a bone marrow aspiration is necessary for confirmation.  The bone marrow is typically 
hypercellular with anywhere from 20% to 100% leukemic blasts.       
1.1.4.3  Standard of Therapy   Standard therapy for AML is divided into two parts; 
remission (induction) and postremission therapy (consolidation therapy).  The role of 
remission induction is to induce a complete response (CR) in patients. The postremission
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therapy goal is to continue the CR or to bridge over to a bone marrow transplant if that is a 
practical option.   
Induction therapy is commonly given in a 3+7 design regardless of cytogenetic 
abnormalities or mutations, with the exception of APL (175).  This combination chemotherapy 
regimen consists of continuous cytarabine (100-200 mg/m2/d) infusion for seven days and either 
high (60-90 mg/m2/d) or low (45 mg/m2/d) dose anthracycline for three days. Both 
chemotherapeutic agents disrupt DNA synthesis however they employ two different 
mechanisms.  Cytarabine is an antimetabolite that incorporates into DNA while anthracyclines 
work through DNA intercalation. This treatment regimen was originally designed back in 1973 
(194) and has had only minimal changes since that time, despite numerous clinical trials (195-
203).  The choice between high and low dose anthracycline is typically made based on age, with 
patients under 65 years old receiving the high-dose regimen and patients over the age of 65 
receiving the low dose.  Daunorubicin is the most common anthracycline given, however 
idarubicin (13 mg/m2/d) can replace the high dose daunorubicin with equal results (204-206).  
Most patients will achieve a CR from only one round of this treatment regimen; however, a 
portion of patients will need additional induction cycles in order to achieve CR.  In AML, the 
definition of CR is a patient with <5% blasts in their bone marrow (207).  However, several 
studies have suggested this definition of CR is inadequate and minimal residual disease (MRD) 
monitoring should consist of more advanced molecular techniques such as PCR to detect 
translocation breakpoints where feasible (208-210). Overall, approximately 65-80% of patients 
will achieve CR with this chemotherapy regimen, while approximately 20% will never achieve 
CR (192).   
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 All AML patients will ultimately relapse without postremission therapy (193). The proper 
postremission therapy is determined by a patient’s cytogenetic profile and can either be 
chemotherapy, allogeneic hematopoietic stem cell transplantation (HSCT) or rarely autologous 
HSCT (207).  A number of clinical trials have been dedicated to determining which patients will 
benefit most from each of these possible postremission therapies.  Generally, in patients with 
favorable cytogenetics (based on the ELN categories) there is no difference in survival between 
chemotherapy or HSCT, and are almost exclusively given chemotherapy (211-215). 
Postremission chemotherapy typically consists of four cycles of high dose cytarabine (3 g/m2) 
given every 12 hours on days 1, 3, 5 (HiDAC) (178, 216, 217).  One exception in the favorable 
group is patients with CBF mutations and concurrent c-KIT mutations (175).  While, these 
patients achieve similar CR rates, they have a substantially increased risk of relapse and thus 
should be considered for HSCT. The proper postremission therapy for patients stratified to the 
intermediate I or intermediate II categories is still debated, although recent studies demonstrated 
increased survival with allogeneic HSCT in these patients (218), particularly those with FLT3-
ITD mutations (219-221). Generally, these patients still receive HiDAC to bridge them over to 
HSCT.  The unfavorable risk group has a clear advantage for allogenic HSCT (222-224).  
Normally <15% of these patients will be alive after 5 years but with allogeneic HSCT the 5-year 
survival rate can be increased to 25% (192).  However, it should be noted that unfavorable 
cytogenetics at diagnosis increases the risk of relapse after allogenic HSCT.  Three mechanisms 
are known to cause relapse after HSCT; failure of response to conditioning regimen, leukemia 
immune escape, or failure to produce effective graft-versus-leukemia response (225). Finally, for 
primary refractory patients, allogenic or autologous HSCT is their only option (226, 227); 
however, outcomes are significantly worse with 3-year survival rates of 19% (228, 229).                   
24 
Even with current treatment, approximately 50-55% of younger patients and 85% of 
older patients will eventually relapse, typically in the first 3 years after remission.  The most 
important predictor of response after relapse is the duration of first remission (184, 192).  
Patients who were in remission for greater than one year are more likely to respond to salvage 
chemotherapy than patients with a remission of less than one year.  While current salvage 
therapies vary, the main priority is to induce a second CR and bridge over to an allogeneic HSCT 
(230).  For patients unable to receive an allogenic HSCT there are not any more options and 
palliative care can be offered (193).   
As it stands, the standard of therapy in AML has changed little in the last 40 years and 
current overall survival rates are approximately 25%.  Elderly patients (5-year overall survival 5-
15%) have a significantly worse prognosis than younger patients (5-year overall survival 35-
40%) (231, 232).  There is a significant unmet need for novel targeted therapies that not only 
increase overall survival but limit toxicities associated with cytotoxic chemotherapy especially in 
older patients.  FLT3 small molecule kinase inhibitors are being intensively investigated for their 
potential as targeted therapy in FLT3-mutated AML and will be discussed in detail in the 
following sections.     
1.2 FLT3 IN NORMAL BIOLOGY AND AML 
Originally cloned in 1991 (233, 234), FLT3 is also known as fetal liver kinase-2 (FLK-2) (235) 
and human stem cell kinase-1 (STK-1) (236).  FLT3 is a member of the class III receptor tyrosine 
kinase family, which also contains platelet-derived growth factor receptor (PDFGR), colony-
stimulating factor 1 receptor (CSF1R or FMS) and the stem cell factor receptor, c-KIT (237).  
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This family of receptor tyrosine kinases is well known for its critical role in hematopoietic 
growth and differentiation.  
1.2.1 Structure of FLT3  
The FLT3 gene consisting of 24 exons, encodes a 1000-amino acid protein with a molecular 
weight of approximately 140 kDa (238). However, upon immunoprecipitation, a 160 kDa band 
also appears, representing a heavily glycosylated form of FLT3 found on the plasma membrane 
(239).  As is typical of the class III receptor tyrosine kinase family, FLT3 contains an 
extracellular region consisting of five immunoglobulin-like (Ig-like) domains (240).  The three 
most N-terminal Ig-like domains are involved in FLT3 ligand (FL) binding while the other two 
are essential for ligand-induced receptor dimerization (241).  A single transmembrane domain is 
followed by the juxtamembrane region.  The tyrosine kinase domain of the receptor tyrosine 
kinase type III family is unique as it contains an ‘insert’ in the middle of the typical bilobed 
kinase domain (240).     
1.2.2 FLT3 activation and signaling in early hematopoiesis 
FLT3 is critical for the growth and survival of CD34+ hematopoietic stem cells and early 
progenitor cells (242, 243).  Interestingly, Flt3-knockout mice develop normal hematopoietic cell 
populations, with the exception of primitive B-lymphoid progenitors (244).  However, bone 
marrow transplanted from Flt3-/- mice failed to reconstitute myeloid cells and T-cells in 
irradiated recipients, supporting a critical role for FLT3 in early hematopoiesis.  Beyond the bone 
marrow, FLT3 is expressed in the liver, thymus, gonads, brain, and placenta (239, 245).   
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 Under normal conditions, receptor tyrosine kinases require ligand binding to promote 
dimerization and autophosphorylation.  In 1993, FLT3 ligand was cloned and proved to be an 
essential proliferative factor for early progenitor cells (246).  During the next couple of years, 
several groups determined that FL is a homodimeric protein expressed as either soluble or 
membrane bound versions within the bone marrow microenvironment (247-250).  Additionally, 
FL is capable of inducing progenitor cell proliferation ex vivo (251-253).     
   FLT3 activation, through binding to FL, stimulates two major downstream signaling 
pathways critical for proliferation and survival.  The phosphoinositide 3-kinase (PI3K) pathway 
is activated through indirect binding to FLT3, conferred through the adapter proteins SHP-2, 
CBL, SHC, GAB-2 and GRB2 (254, 255).  PI3K activates AKT and mTOR downstream, which 
in turn increases p70S6K activity and reduces Forkhead transcription factor activity.  As a result, 
pro-apoptotic signaling is reduced, enhancing survival and cell cycle progression.  RAS 
activation is mediated through the guanine nucleotide exchange factor Son of Sevenless (SOS) 
(256, 257).  RAS activation stimulates the MEK/ERK pathway downstream, leading to increased 
transcriptional activity of CREB.   The RAS pathway promotes proliferation upon FL binding.  
In addition to these two major pathways PLCγ-1 is activated as well as SRC and FYN, both of 
which physically interact with the active FLT3 receptor (258).     
1.2.3  FLT3 mutations in AML 
Approximately 70-100% of AML cases express high levels of FLT3, irrespective of cytogenetics 
or age (259-261).  It should be noted that FLT3 is also expressed at high levels in most cases of 
B-ALL, T-ALL, and in a small percentage of CML cases (262).  It is likely FLT3 promotes 
survival and proliferation of the leukemic blasts through activation by FL (263). In fact, one 
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study found that a significant proportion of leukemic blasts express both FLT3 and FL 
suggesting an autocrine signaling loop (264).  Although wild-type FLT3 (FLT3-WT) is highly 
expressed in multiple types of leukemia, FLT3 mutations show considerable specificity for 
AML. 
1.2.3.1  FLT3-ITD mutations  The internal tandem duplication (ITD) mutation of FLT3 was 
originally discovered in 1996 in 5 of 30 patients with AML (265).  Subsequent sequence 
analysis showed that this type of mutation occurs in-frame and was a duplication of a 
portion of the juxtamembrane region of FLT3.  Subsequent studies confirmed these results, 
and today it is well established that FLT3-ITD mutations occur in approximately 25% of all 
AML cases and most commonly occur in CN-AML (266-269).  ITDs typically insert in 
exons 14 and 15 of FLT3 and their length can vary significantly, from 3 bps to well over 
a 100 bps.  FLT3-ITD mutations commonly occur in only one allele of FLT3 but interestingly, 
the FLT3-WT allele is lost is some cases of FLT3-ITD+ AML suggesting that loss of the 
FLT3-WT allele may confer a survival advantage (270, 271).   
The structural basis for constitutive activation of FLT3 by an ITD was discovered in 2004 
with the crystallization of an autoinhibited FLT3-WT kinase domain (272).  This study revealed 
that the juxtamembrane region docks onto the back of the kinase domain and locks it in a 
downregulated state.  Thus, lengthening of this region, via an ITD, could disrupt the 
autoinhibition caused by the juxtamembrane region resulting in a constitutively active kinase in 
the absence of FL binding.  
FLT3-ITD continuously activates the PI3K and RAS pathways, similar to FLT3-WT, but 
has gained the ability to activate numerous other downstream signaling pathways as well. The 
activation of STAT5 is one of the most established downstream effectors of FLT3-ITD (273).  
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While studies disagree on whether STAT5 binds directly to FLT3 or it is activated by other 
tyrosine kinases linked to FLT3, it is agreed upon that STAT5 transcriptional regulation is 
essential for the expression of the anti-apoptotic proteins BCL-xL, PIM kinases, and c-MYC 
(274-277).  In addition, to the activation of STAT5, FLT3-ITD downregulates both CEBPA and 
PU.1, transcription factors essential for myeloid cell differentiation (278).  Other studies have 
also demonstrated that FLT3-ITD synergizes with WNT signaling through the upregulation of 
the WNT ligand, Frizzled-4 (279).  Finally, FLT3-ITD can increase reactive oxygen species 
(ROS) in leukemic cells which likely increases genomic instability and lead to further mutations 
(280).  
1.2.3.2  FLT3-TKD mutations  In 2001, tyrosine kinase domain (TKD) point mutations were 
reported in FLT3, analogous to mutations previously identified in other receptor tyrosine 
kinases such as c-KIT and MET (281).  These mutations most commonly occur in the 
activation loop at amino acid D835.  While tyrosine substitutions (D835Y) are the most 
common mutation, valine, histidine, glutamate, and asparagine mutations also occur.  
Additionally, in rare cases I836 is mutated, instead of D835, to methionine or asparagine (281, 
282).  Overall, TKD mutations occur in approximately 5-7% of all AML cases and are most 
common in CN-AML (283, 284).  Additionally, one study concluded that TKD mutations 
are mutually exclusive with ITD mutations (285).          
The activation loop of the FLT3 kinase domain is localized between the N-lobe and C-
lobe of the kinase domain, and adopts a specific conformation in the inactive state.  However, 
mutations in the activation loop disrupt this loop packing and prevent inactivation, resulting in 
constitutive kinase activity (8).  FLT3-TKD mutations can transform cells to cytokine-
independent growth and activate similar pathways as FLT3-ITD mutations, including PI3K, 
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RAS/MAPK, and STAT5 (286). However, there are signaling differences.  For example, even 
though studies indicate FLT3-TKD phosphorylates STAT5, one study discovered only weak 
expression of STAT5 target genes suggesting that FLT3-ITD creates a more robust activation of 
STAT5 (287).  Additionally, CEBPA and PU.1 inactivation are crucial downstream effects of 
FLT3-ITD signaling (278).  However, FLT3-TKD mutants are not capable of inactivating these 
two transcription factors (287).  Another study discovered that FLT3-ITD can activate SRC as an 
effector kinase but FLT3-TKD was incapable of activating SRC (288).  My own work shows that 
FLT3-ITD, but not FLT3-TKD, activates the FES tyrosine kinase downstream (Appendix A). 
Transgenic mouse studies also support differences between FLT3-ITD and FLT3-TKD 
mutations.  FLT3-ITD expression in mice only drives a myeloproliferative neoplasm (MPN), not 
overt AML (16).  The majority of FLT3-TKD mice also develop a MPN; however, it is less 
aggressive than the MPN driven by FLT3-ITD, with FLT3-TKD mice surviving significantly 
longer than FLT3-ITD expressing mice (289).  Interestingly, FLT3-TKD mutations developed 
into more than just an MPN, as some mice developed lymphomas or sarcomas.  Additionally, 
FLT3-ITD mice display a loss of long-term hematopoietic stem cells (LT-HSCs), potentially 
because FLT3-ITD forces these cells to proliferate instead of self-renew (290).  However, FLT3-
TKD mice display no such differences in LT-HSCs (289).  Furthermore, FLT3-TKD mice 
display reduced myeloid expansion and similar engraftment ability as FLT3-WT expressing 
mice.  Overall, the signaling differences and mouse data present a story where FLT3-TKD 
mutations behave quite differently than FLT3-ITD mutations.     
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1.2.4  Prognostic impact of FLT3 mutations 
Given the differences mentioned above, it is not surprising that patients with FLT3-ITD or FLT3-
TKD mutations have different prognoses.  The prognostic impact of FLT3-TKD mutations is still 
controversial, but it is generally agreed that the prognosis is better than a FLT3-ITD mutation.  
Several studies determined that FLT3-TKD mutations have similar overall survival and event-
free survival as FLT3-WT patients (291-293).  However, two studies have indicated that FLT3-
TKD mutations adversely affect overall survival (281, 294).  Although the reason for these 
differences is not understood, one possibility is differences in the patient cohorts.  Differences in 
cytogenetics or patients’ ages could confound the effects observed since it is highly unlikely that 
FLT3-TKD mutations occur in isolation.   
 In contrast to FLT3-TKD mutations, FLT3-ITD mutations are an independent poor 
prognostic marker (295-300). ITD mutations are linked to significantly higher white blood cell 
and blast counts, as well as lower overall survival (271).  Interestingly, a hemizygous FLT3ITD/- 
genotype confers an even worse prognosis than heterozygous FLT3WT/ITD (270).  The reason for 
this is not understood, but it is possible that FLT3-WT can interfere with FLT3-ITD signaling, 
possibly by maintaining expression of differentiation-related genes. ITDs have limited impact on 
complete remission rates; however, relapse rates are significantly higher and thus allogeneic 
HSCT is offered as the best consolidation therapy after remission (263).   
 The average length of an ITD is approximately 30-50 amino acids.  However, as stated 
earlier, ITDs can vary from 3 amino acids to well over 100 amino acids.  Recent studies have 
begun to explore the possibility that a longer ITD confers a worse prognosis.  In support of this 
hypothesis, two studies determined that patients with long ITDs (>40 amino acids or >48 amino 
acids) conferred a worse event-free survival and overall survival (301, 302).  The structural basis 
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for this is not understood but one possibility is that a longer ITD provides more binding sites for 
interacting proteins or potentially allows FLT3 to bind to new effector kinases. 
 The allelic burden of FLT3 is also being investigated as a prognostic maker in FLT3-
ITD+ AML.  Most FLT3-ITD+ AML patients carry one FLT3-WT allele.  However, the 
expression levels of FLT3-ITD versus FLT3-WT vary significantly between patients.  Several 
studies have discovered that a higher FLT3-ITD allelic burden (ratio > 0.5 of FLT3-ITD/FLT3-
WT) conferred significantly worse event-free survival and overall survival (20, 303, 304).  
However, it should be noted that the ITD always carries a poor prognosis, even if it is short and 
has a low mutant allele burden.  These studies are subdividing the poor prognosis group further 
to identify more prognostic markers.  Finally, one study investigated both mutant allele burden 
and ITD length (305).  They discovered that the prognostic effects of these two makers were 
additive, but not synergistic.   
1.3 TYROSINE KINASE SIGNALING IN FLT3-ITD+ AML 
As described previously, FLT3-ITD has many downstream effector kinases.  In this section I 
want to explore a few particular tyrosine kinases that are activated downstream of FLT3-ITD and 
are crucial for my dissertation research.  Additionally, I will provide a brief background on the 
discovery of these kinases and their normal functions.   
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1.3.1 Src-Family Kinases (SFKs) 
The Src-family is the largest family of non-receptor tyrosine kinases in the human genome.  The 
first family member discovered, c-SRC, (hereafter referred to as ‘SRC’) is the cellular homolog 
of the transforming oncogene in Rous Sarcoma Virus (RSV), v-Src.  RSV was originally 
discovered in the early 1900s as a virus capable of inducing rapid tumor growth in chickens 
(306).  However, it was not until the 1970s that v-Src was determined to be the cancer-driving 
protein expressed by the RSV genome (307).  In addition, v-Src was the very first tyrosine kinase 
discovered; which opened the door to the discovery of many other transforming tyrosine kinase 
oncogenes and their normal cellular counterparts.  Since the discovery of SRC, seven other Src-
family kinase (SFK) members have been described in humans: HCK, LYN, FGR, LCK, BLK, 
YES, and FYN (308). Three of the family members, SRC, YES, and FYN, are expressed in 
almost all cell types while LYN, HCK and FGR expression is restricted to myeloid cells (309).  
LCK expression is restricted to T-cells, while BLK displays restricted expression in B-cells.  
LYN is also expressed in B-cells.  Generally, the SFKs facilitate the integration of signals from 
numerous upstream sources (cytokines, growth factors, cell attachment, others) to signaling 
pathways downstream.  The SFKs are critical for signaling pathways related to cell proliferation, 
motility, survival, and invasion.  A detailed description of individual SFK function is beyond the 
scope of my dissertation.  Additional background information given below is limited to the role 
of the myeloid SFKs, HCK, LYN, and FGR, normal hematopoiesis and in AML.   
    HCK, FGR, and LYN have key roles in a number of signaling pathways in myeloid 
cells, including lipopolysaccharide (LPS) responses (310), FcγR signaling (311, 312), as well as 
granulocyte-macrophage colony stimulating factor (GM-CSF) (313) and granulocyte colony 
stimulating factor (G-CSF) (314) signaling. Hck, Fgr, and Lyn triple knock-out mice have greatly 
 33 
enhanced our understanding of the role of the SFKs in hematopoietic cells.  Hck-/- and Fgr-/- 
single knockout mice displayed no significant differences from wild-type mice, potentially 
because of functional overlap with other SFKs (315).  However, the Hck-/-Fgr-/- double knockout 
mice showed significant defects in the innate immune response to the intracellular pathogen, 
Listeria monocytogenes, a significant source of food-borne illness (315). Additionally, while 
macrophages from these mice displayed no defects, LYN activity was upregulated suggesting 
compensation for the lack of HCK and FGR (315).  Furthermore, integrin signaling in 
neutrophils was completely blocked in the double knockout mice (316).  Finally, Hck-/-Fgr-/- 
neutrophils have significantly reduced migration (317) and adhesion (318).  
 Lyn-/- mice present with reduced numbers of recirculating B-cells that is likely the result 
of reduced B-cell receptor signaling (319).  Additionally, Lyn-/- mice have a reduced ability to 
eliminate autoreactive B-cells, resulting in widespread autoimmunity (319).  Finally, mast cell 
function is abrogated in Lyn-/- mice due to the signaling function of LYN downstream of the 
FcεR1 (319).  Hck-/-Fgr-/-Lyn-/- triple-knockout mice display significant defects in FcγR-mediated 
phagocytosis in macrophages (320, 321).  Additionally, innate immune responses were blunted 
for a number of pathogens (322).  Subsequent studies have suggested the innate immune 
response defects stem from an inability to generate and release pro-inflammatory mediators 
(323).  
 The first evidence for HCK, LYN, and FGR involvement in a hematologic malignancy 
was described for chronic myelogenous leukemia (CML).  CML is driven by the reciprocal 
translocation of chromosome 22 and chromosome 8 that juxtaposes the breakpoint cluster region 
(BCR) and ABL tyrosine kinase genes.  This translocation creates what is known as the 
Philadelphia chromosome, named for the city in which it was discovered (324).  The 
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Philadelphia chromosome drives expression of a fusion protein, BCR-ABL, a constitutively 
active ABL kinase that drives CML pathogenesis.  HCK and LYN were originally implicated in 
CML with the discovery that BCR-ABL binds and activates these kinases (325).  Subsequent 
work revealed that the reciprocal is also true, that HCK and LYN phosphorylate BCR-ABL and 
as a result may increase its kinase activity and sensitivity to imatinib (326).  Imatinib (Gleevec) 
is a relatively selective, orally active inhibitor of BCR-ABL that was FDA-approved in 2001 as 
the first-line therapy for CML patients.  Additionally, a kinase-dead version of HCK has been 
shown to suppress the transforming activity of BCR-ABL in a myeloid cell line, suggesting a 
specific and necessary role for HCK in CML pathogenesis (327).  Up-regulation of HCK (328, 
329) and LYN (330, 331) expression has also been linked to imatinib resistance in CML in the 
absence of BCR-ABL mutations.  Interestingly, the second tyrosine kinase inhibitor to receive 
FDA approval for CML therapy was dasatinib (Sprycel).  This compound is a potent inhibitor of 
both ABL and SFKs, which may account for its improved efficacy and reduced resistance 
potential in CML (332).  
 Mounting evidence implicates HCK, LYN, and FGR in FLT3-ITD+ AML as well.  In 
2005, LYN was discovered to be active downstream of FLT3-ITD and a SFK inhibitor, PP1, 
reduced the growth of FLT3-ITD+ AML cell lines (333).  However, subsequent work has 
established that PP1 is a broad-spectrum tyrosine kinase inhibitor that targets all of the SFKs as 
well as numerous other kinases (334).  Thus PP1 is not useful as a probe compound to 
specifically implicate LYN kinase activity in FLT3-ITD+ AML, because it also inhibits HCK and 
FGR among other targets.  Subsequent studies discovered that LYN binds to a phosphorylated 
tyrosine site in FLT3-ITD via its SRC Homology 2 (SH2) domain and that small interfering 
RNA (siRNA) knockdown of LYN reduces STAT5 phosphorylation (335).  Additionally, the 
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SFK inhibitor, PP2, reduced tumor growth in a xenograft model of FLT3-ITD+ AML.  Follow up 
studies demonstrated that LYN is active in primary AML patient samples and that PP2 inhibits 
this activation (336).  This study also demonstrated that LYN silencing by siRNA inhibits mTOR 
signaling independent of AKT.  Finally, this was the first study to demonstrate that both HCK 
and FGR are also constitutively active in primary AML patient samples.                  
 Recently a breakthrough discovery occurred when HCK was identified as being 
differentially expressed in LSCs versus normal HSCs (337).  As described earlier, LSCs are 
notoriously difficult to eliminate because they are chemotherapy-resistant and largely quiescent, 
making the identification of a targetable kinase an important step in AML therapy.  Furthermore, 
Saito et. al. (338) demonstrated that shRNA knockdown of HCK reduced the growth of FLT3-
ITD+ AML cells. Additional work identified an HCK inhibitor, RK-20449 (previously reported 
in the literature as A-419259), that is efficacious against chemotherapy-resistant primary AML 
bone marrow samples (338).  RK-20449 reduced the growth of patient-derived xenograft models 
of AML in PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice.  Finally, secondary transplantation experiments 
demonstrated that RK-20449 treated samples failed to engraft secondary recipients, suggesting 
the elimination of LSCs in these samples.  
  FGR is the least well studied of the myeloid-restricted SFKs with respect to its role in 
AML.  Several studies, including my thesis, have identified a dichotomous expression pattern for 
FGR in AML; it is either expressed at very high levels or very low levels (336, 339).  One study 
showed that knockdown of FGR expression reduces FLT3-ITD AML cell growth and colony 
formation in soft agar (339).  I will note that previous studies used small molecule kinase 
inhibitors that do not discriminate among SFKs, which suggests that even though a role for FGR 
was not directly investigated, FGR cannot be ruled out as a contributor to the efficacy of those 
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compounds.  This includes RK-20449, which we found to inhibit not only HCK but also LYN, 
FGR and FLT3-ITD itself.  This issue is described in more detail in Chapter 2. 
1.3.2 SYK Tyrosine Kinase        
Originally, purified from bovine thymus and porcine spleen, spleen tyrosine kinase (SYK) is 
expressed at high levels in many hematopoietic cell types (340-342).  Numerous studies 
demonstrated that SYK is responsible for signaling downstream of immune receptors.  Integrin 
signaling is critical for proper adhesion and migration of a number of different cell types, 
including neutrophils, monocytes, platelets, and osteoblasts (343-347).  In each of these cell 
types, integrin signaling is ablated or reduced in SYK-deficient cells (348).  SYK is also critical 
for pathogen recognition downstream of pattern recognition receptors (349-351). Receptors 
responsible for the recognition of fungal, bacterial, and viral infection all depend on SYK 
signaling with one study demonstrating that bacterial infection host defenses are attenuated in 
Syk-/- animals (352).  FcR signaling in mast cells and neutrophils is also attenuated with SYK 
deficiency (353-355), while antibody-dependent cell-mediated cytotoxicity (ADCC) is reduced 
in natural killer cells lacking SYK (356).  Finally, SYK is indispensable for B-cell maturation 
and B-cell receptor signaling.  Syk-deficient animals have a complete absence of mature B-cells.   
 Several studies discovered that the Epidermal Growth Factor Receptor (EGFR) inhibitor, 
gefitinib, is capable of inducing differentiation in AML cells through a non-EGFR dependent 
mechanism, as AML cells do not express EGFR (357-359). In 2009, through integration of 
chemical, proteomic, and genomic screening approaches, SYK was identified as the target of 
gefitinib in AML cells (360). Further investigation revealed that small hairpin RNA (shRNA) 
knockdown and small molecule inhibition of SYK can induce differentiation in a diverse set of 
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AML cell lines.  Finally, SYK inhibition was efficacious in vivo and against primary AML 
patient samples.  Subsequent studies from the same laboratory revealed that SYK is most active 
in FLT3-ITD+ AML samples and is able to directly bind to FLT3-ITD (361).  Furthermore, 
activation of c-MYC is dependent on SYK activity and overexpression of SYK is capable of 
inducing resistance to targeted small molecule FLT3-ITD kinase inhibitors. This finding suggests 
that inhibitors with dual activity against FLT3 and SYK may be less prone to acquired resistance, 
in a manner analogous to dasatinib in CML.  I will return to this theme in detail in the next 
chapter. 
1.3.3 FES Tyrosine Kinase 
c-FES (hereafter referred to as ‘FES’) was originally identified as the cellular homolog of the
transforming oncogenes of Fujinami avian sarcoma virus (v-Fps), Gardner-Arnstein feline 
sarcoma virus (v-Fes), and Snyder-Theilen feline sarcoma virus (v-Fes) (362-366).  In 1985 the 
complete sequence of the human FES gene was reported and it was discovered that FES belongs 
to a unique family of non-receptor protein tyrosine kinases (367).  FES is highly expressed in 
hematopoietic cells (368),  particularly those of the myeloid lineage, but it is also expressed at 
lower levels in endothelial cells, epithelial cells of the breast and gut as well as some neuronal 
cells (369).  FES was originally discovered in terminally differentiated myeloid cells suggesting 
a role in myeloid differentiation.  In support of this hypothesis, ectopic expression of FES in a 
non-terminally differentiated myeloid cell line, K562, caused the cells to undergo terminal 
differentiation (370).  Furthermore, two studies discovered activation of the essential 
differentiation transcription factors, CEBPA and PU.1, was driven through FES (371, 372). One 
study also discovered that FES was essential for the survival of terminally differentiated cells 
38 
(373).  However, a Fes-/- mouse model displayed no defects in myeloid cell differentiation or 
survival (374, 375).  Similar to the SFK knockout mouse models, it is possible that other kinases, 
especially the closely related FER kinase, compensated for the loss of FES.  One interesting 
phenotype from the Fes-/- mouse model was its increased sensitivity to lipopolysaccharide (LPS) 
(376).  FES is abundantly expressed in innate immune cells, particularly neutrophils and 
macrophages, so Fes potentially regulates inflammation.  Subsequent studies revealed an 
essential role for Fes in macrophage chemotaxis (377).  Additionally, FES is implicated in a 
number of signaling pathways downstream of growth factor and cytokine receptor tyrosine 
kinases, including GM-CSF, IL-3, IL-4, and IL-6 (378). A possible role for FES in outside of 
myeloid cells was discovered when an activated form of FES bearing the SRC N-terminal 
myristoylation signal sequence was introduced into transgenic mice under the control of the 
natural promoter.  These mice developed vascular hyperplasia and multifocal hemangiomas 
suggesting a role for FES in angiogenesis (379).  The role for FES endothelial cell migration and 
vascular tube formation has been confirmed in several subsequent studies (380).   
FES was originally described as a proto-oncogene because of its homology to the cancer-
promoting viral oncogenes described above.  However, FES mutations discovered in cancer cells 
to date have been inactivating mutations suggesting a tumor suppressor role for FES.  These 
dichotomous roles are likely caused by tissue specific functions of FES.  For example, FES-
inactivating mutations, as well as promoter methylation that silences FES expression, were 
discovered in human colon cancer cell lines and patient samples (381, 382) while pro-
tumorigenic functions have been described in leukemia and some brain tumors (383).  While 
FES has potential roles in many cancers, I will focus on the role of FES downstream of FLT3-
ITD in AML.  FES was originally identified as activated downstream of FLT3-ITD in two FLT3-
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ITD positive cell lines, MV4-11 and MOLM-14 (384).  Knockdown of FLT3 by siRNA 
eliminated FES phosphorylation indicating that activation was FLT3-ITD-dependent. 
Furthermore, expressing exogenous FLT3-ITD in a myeloid cell line that does not normally 
express FLT3, TF-1, activated endogenous FES.  However, FES is active in a FLT3-WT cell 
line, THP-1, and knockdown of FLT3 has no effect on its activity.  This suggests that other 
mechanisms are capable of activating FES.  Knockdown of FES by siRNA reduced the growth of 
both MV4-11 cells and MOLM-14 cells and resulted in impaired cell cycle progression.  
Additionally, knockdown of FES inhibited signaling downstream of FLT3-ITD.  In particular, it 
reduced STAT5 activation, blocked activation of many PI3K pathway members, and reduced 
expression of the antiapoptotic protein BCL-xL.  Finally, FES is activated in primary AML 
patient bone marrow samples.  These studies suggest that targeted inhibition of FES kinase 
activity may be of therapeutic benefit in AML. 
1.4 TARGETING FLT3 MUTATIONS IN AML 
Given the evidence that FLT3 mutations drive approximately 30% of AML cases, it is not 
surprising that the development of small molecule inhibitors of FLT3 is of considerable interest 
for AML therapy.  However, unlike imatinib, which revolutionized the treatment of CML, FLT3 
inhibitors have had limited clinical success.  In this section I will detail the first- and second-
generation FLT3 inhibitors tested in clinical trials and explore the reasons for their limited 
success in the clinic. 
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1.4.1 First-Generation FLT3 inhibitors 
The first-generation FLT3 inhibitors were a group of small molecule receptor tyrosine kinase 
inhibitors not necessarily developed to inhibit FLT3 specifically.  In fact, all of the inhibitors hit 
a broad range of receptor tyrosine kinases and have also been tested in clinical trials for other 
solid and liquid tumors.  
Sunitinib, a multi-targeted inhibitor of FLT3 and the homologous receptor tyrosine 
kinases c-KIT, colony stimulating factor 1 (CSF) receptor, PDGFR, GDNF receptor (RET), and 
vascular endothelial growth factor receptor (VEGFR), is approved for use in metastatic renal cell 
carcinoma and gastrointestinal stromal tumors (385).  Sunitinib inhibits FLT3 in patients with 
kinase inhibition directly proportional to plasma drug levels (386).  In phase I clinical trials, as a 
single agent, sunitinib induced partial responses in AML patients that lasted between 4-16 weeks 
(387).  Most patients experienced peripheral blast count decreases but no reduction in bone 
marrow blasts.  Single agent phase II clinical trials were never pursued due to the short duration 
of response and the significant toxicities.  However, a phase I/II combination trial with standard 
therapy (cytarabine plus high dose anthracycline) produced a complete response rate of 53% in 
FLT3-ITD+ patients (388).  Interestingly, the complete response rate for FLT3-TKD+ patients in 
this study was only marginally higher at 73%, suggesting a potential role for this inhibitor 
outside of FLT3-ITD+ AML.  Several patients were transitioned onto single agent maintenance 
therapy, with a median response duration of 11 months.     
    Lestaurtinib (CEP-701), a staurosporine derivative known to target JAK2, VEGFR, 
and tropomyosin receptor kinase (TRKA) as well as FLT3 has been tested in a number of clinical 
trials (385).  A phase II trial of AML patients refractory to standard treatment resulted in a 
clinical response (partial or complete response) for 36% of the patients (389).  However, as with 
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sunitinib, the responses were short lived, lasting anywhere from 2 weeks to 3 months.  In another 
phase II clinical trial, older patients deemed not fit for standard therapy received lestaurtinib 
(390).  While some patients exhibited transient peripheral and bone marrow blast reduction, there 
was no difference between FLT3-ITD and FLT3-WT response rates, suggesting that off-target 
effects were at least partially responsible for the efficacy.  Finally, in a phase III combination 
clinical trial patients in first relapse received lestaurtinib after chemotherapy (391).  No 
difference in response rates or overall survival was reported.  However, a follow up study 
indicated that as opposed to the other clinical trials, most patients in this study did not achieve 
FLT3 inhibition (392).  
 Tandutinib (MLN-518), a targeted inhibitor of FLT3, c-KIT, and PDGFR, was tested in 
both phase I and phase II clinical trials (385).  In both studies, tandutinib had dismal efficacy and 
produced no complete or partial responses (393).  In a combination trial the response rate 
increased, however a limited number of patients had FLT3 mutations and response was likely 
due to chemotherapy (394).  No further clinical trials were ever pursued with tandutinib.   
 Midostaurin (PKC-412), another staurosporine derivative, targets FLT3, c-KIT, CSFR1, 
VEGFR, protein kinase C alpha (PKC-α) and PDGFR (385) and has been tested in phase I, II, 
and III clinical trials.  In a phase II clinical trial, as a single agent, midostaurin reduced peripheral 
and bone marrow blasts in 71% of FLT3-ITD+ patients (395).  Median response duration from 
that clinical trial was 13 weeks. A small combination phase Ib clinical trial in young, newly 
diagnosed AML patients produced a 92% complete response rate in FLT3-mutated AML patients 
(396).  The combination of midostaurin with standard chemotherapy increased disease-free 
survival and overall survival to a level similar to FLT3-WT patients.  The results of a 
combination phase III clinical trial that accrued over 700 patients were reported in 2015 (397).  
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The addition of midostaurin to induction and consolidation therapy plus use of midostaurin as 
maintenance therapy increased the median overall survival from 26 months to 75 months.  
Event-free survival was also increased from a median of 3 months to a median of 8 months.  This 
is the first clinical trial to demonstrate a significant improvement in therapy with the addition of 
a FLT3 inhibitor.   
Sorafenib, a FLT3, c-KIT, RAF, PDGFR, and VEGFR inhibitor  currently approved for 
use in renal cell carcinoma and hepatocellular carcinoma (385), is capable of eliminating 
peripheral blasts and reducing bone marrow blasts in FLT3-ITD+ patients, with a median 
response time of 72 days (398).  Sorafenib exhibits no efficacy in AML patients with FLT3-TKD 
mutations, however, because these mutants are resistant to the inhibitor.  A combination clinical 
trial of chemotherapy plus sorafenib had a complete response rate of 93% in FLT3-ITD+ patients 
(399).  However, at the follow up time of nine months, half of the patients had relapsed. Another 
combination clinical trial in elderly patients demonstrated no benefit with the addition of 
sorafenib (400).  However, only a small proportion of the patients were FLT3-ITD+.  Several 
clinical trials demonstrated longer remission and reduced resistance with the use of sorafenib 
after allogenic HSCT (401-403).  This suggests that sorafenib may synergize with the allogeneic 
hematopoietic stem cell transplant, through an unknown mechanism.   
1.4.2 Second-generation FLT3 inhibitors 
Two important lessons were learned during clinical trials with the first-generation FLT3 
inhibitors.  The first is that targeting FLT3 proved more efficacious in FLT3 mutated patients 
over FLT3-WT patients.  Additionally, FLT3 inhibitors proved more effective in patients 
carrying a high mutant allelic ratio of FLT3. The second is that clinical response closely mirrored 
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sustained FLT3 inhibition in vivo (404).  Whereas the first-generation FLT3 inhibitors were 
designed to inhibit multiple receptor tyrosine kinases, the second-generation FLT3 inhibitors 
were purposefully designed for potency and specificity in targeting FLT3.  Additionally, some of 
the inhibitors were purposefully designed to be efficacious against FLT3-TKD mutants.   
 Quizartinib (AC220) was the first inhibitor purposefully designed to inhibit FLT3, 
although it also inhibits c-KIT and PDGFR (385).  In phase I/II clinical trials in elderly patients 
with relapsed or refractory disease, quizartinib had a complete response rate of 53% in FLT3-
ITD+ patients (405).  To date, this is the greatest single agent efficacy of a FLT3 inhibitor.  A 
similar result was achieved in a phase II clinical trial exploring the efficacy of quizartinib in 
young relapsed or refractory patients (406).  Numerous clinical trials are currently assessing 
quizartinib as a potential agent for combination with standard chemotherapy or as a single agent 
in non-relapsed patients.  One major side effect of quizartinib is QTc prolongation.  This is 
currently the dose limiting toxicity of this compound.   
 Crenolanib is in clinical trials for a number of solid tumors due its efficacy against 
PDGFR.  However, recently crenolanib proved to be a potent inhibitor of FLT3.  More 
importantly, crenolanib is capable of inhibiting several FLT3-TKD mutations that are resistant to 
quizartinib (407).  Furthermore, crenolanib exhibits no QTc prolongation and demonstrates 
selectivity for FLT3 over c-KIT.  c-KIT inhibition is thought to be the cause of 
myelosuppression, a common side effect of treatment with FLT3 inhibitors. Crenolanib could 
potentially reduce myelosuppression after treatment, leading to faster recovery times for patients.  
A phase I clinical trial with crenolanib as monotherapy in relapsed or refractory AML 
demonstrated an overall response rate of 50% (408). Currently, crenolanib is under investigation 
in two phase II clinical trials.   
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 PLX3397 is a FLT3 inhibitor that exhibits selectivity for FLT3-ITD over FLT3-WT.  
Additional targets include c-KIT and CSFR1 (409).  One advantage of PLX3397 is its activity 
against a common quizartinib-resistant mutant, FLT3-F691L. However, patients with FLT3-
D835 mutations are insensitive to PLX3397.  Currently, PLX3397 is in a phase I/II clinical trial 
and no results have been reported yet.       
 TTT-3002 is a staurosporine derivative developed in the laboratory of Donald Small.  
This compound potently targets FLT3 and exhibits picomolar potency against some FLT3-ITD 
cell lines (410).  Additionally, this compound also exhibited potency against primary AML 
patient samples and in vivo models of AML.  Finally, TTT-3002 is efficacious against most 
known FLT3-TKD mutations, including the common quizartinib inhibitor resistant mutations 
(411).  No clinical trials have been started yet for this compound.  
 Two drugs normally used in the treatment of CML, dasatinib and ponatinib, are currently 
in clinical trials for use in AML.  Ponatinib is efficacious against FLT3-ITD and FLT3-TKD 
mutations and is being explored against inhibitor resistant mutations of quizartinib (412).  
Dasatinib does not inhibit FLT3 and likely works through the inhibition of a number of non-
receptor tyrosine kinases (413).  Both compounds exhibit efficacy against AML cell lines, 
primary patient samples, and in vivo models of AML.   
1.4.3 Resistance mechanisms to targeted FLT3 inhibitors 
Clinical FLT3-targeted inhibitors are beginning to show efficacy as single agents and in 
combination therapies.  However, response durations are transient, likely because of acquired 
resistance.  Numerous resistance mechanisms have been described and will be detailed below.   
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1.4.3.1 FLT3-dependent resistance mechanisms  The most common resistance mechanism 
observed with FLT3 inhibitor treatment is selection for inhibitor resistance mutations in FLT3.  
These have been observed for almost all inhibitors and the different chemical classes of 
inhibitors have unique mutation patterns.  For example, resistance to quizartinib, which 
often overlaps with sorafenib resistance, occurs most commonly through F691L (also F691I), 
D835Y (also D835V and D835F) and Y842C (Figure 3) (414, 415).  However, these FLT3-ITD-
TKD mutants are still sensitive to the staurosporine derivatives (416). Fewer studies have 
identified resistance mutations to the staurosporine derivatives.  However, mutations at N676 
(most commonly N676D) and G697 (most commonly G697R) confer resistance to 
midostaurin (Figure 3) (417).  It should be noted that newly diagnosed patients with FLT3-ITD-
TKD mutations have significantly worse outcomes than patients with FLT3-ITD alone 
(418).  One potential mechanism for the worse prognosis is the upregulation of anti-
apoptotic proteins, such as BCL-xL.  Not only would these patients be refractory to FLT3 
tyrosine kinase inhibitors, but they are also less sensitive to cytotoxic chemotherapy.  This 
suggests that the development of resistance mutations in the presence of a FLT3-ITD mutation 
may decrease these patients’ overall survival.   
Another FLT3-dependent mechanism of resistance is the upregulation of FLT3 ligand 
(FL).  As described earlier, most AML blast cells express both FLT3 and FL, suggesting an 
autocrine loop.  While FLT3-ITD does not need FL for activation, it remains highly sensitive to 
stimulation by FL which leads to proliferation of leukemic blasts (419). In this way FL can 
interfere with inhibition of FLT3. One in vitro study demonstrated reduced potency of FLT3 
inhibitors against the FLT3-ITD positive cell line, MOLM-14, in the presence of FL (420).  
Upregulation of FL is commonly observed after treatment with FLT3 inhibitors.  Furthermore, it 
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is well established that standard chemotherapy induces large upregulation of FL expression (391, 
420-422), potentially explaining why FLT3 inhibitors are more efficacious in newly diagnosed 
patients than relapsed patients. This upregulation of FL is also an issue when trying to determine 
the best timing for combination therapy. 
 One final FLT3-dependent mechanism of resistance is the upregulation of FLT3 itself, 
which could possibly overwhelm the inhibitor at physiological doses (423).  One study 
discovered upregulation of FLT3 surface expression in 13 of 14 patients treated with FLT3 
inhibitors.  It was noted that no gene duplications were observed.   
 
Figure 3: X-Ray crystal structure of FLT3 inhibitor resistant mutations. 
The x-ray crystal structure of FLT3 displaying the location of the most common FLT3 inhibitor resistant mutations 
(PDB ID: 1RJB).  Quizartinib and Sorafenib mutations most commonly occur on the activation loop (D835 and 
Y842) and at the ‘gatekeeper’ position (F691) while midostaurin resistance occurs in two residues at the back of the 
ATP binding pocket (N676 and G697).  
N-lobe 
C-lobe 
Activation 
 Loop 
D835 
Y842 
G697 
N676 F691 
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1.4.3.2 FLT3-independent resistance mechanisms  AML blast cells reside in bone marrow 
niches that are critical for the survival of the blast cells.  The bone marrow environment is 
potentially a physical barrier to some inhibitors, simply not allowing the FLT3 inhibitors 
to come in contact with the bone marrow AML blasts.  Additionally, the niche 
provides a number of survival signals through physical contact and the release of cytokines 
(424, 425).  Co-culture of FLT3-ITD+ cells in the presence of bone marrow stromal cells 
demonstrated that FLT3 inhibitors fail to inhibit STAT5 signaling in the presence of stroma, 
even if FLT3 is inhibited.  One potential explanation for this discrepancy is that stromal 
cells can induce the activation of ERK and AKT pathways in the presence of FLT3 
tyrosine kinase inhibitors (424).   
Similarly, the upregulation of compensatory pathways is observed after 
prolonged treatment with FLT3 inhibitors.  In separate studies, the PI3K/AKT (426), STAT 
(427), and MEK/ERK (428) pathways have been identified as upregulated and responsible for 
resistance to FLT3 inhibitors. Furthermore, this upregulation often occurs in the presence of 
FLT3 inhibition, suggesting selection for alternative driver mutations.  These mechanisms are 
likely connected to the effect of stromal cells mentioned earlier.  One study described resistance 
to FLT3 inhibitors through the development of other driver mutations such as N-RAS-
activating mutations (428).  Other compensatory mechanisms have been described, as some 
cell lines express high levels of anti-apoptotic proteins as a resistance mechanism to FLT3 
inhibitors (429-431).  The driver for this upregulation is unknown.
Leukemic stem cells contain a significant FLT3-independent mechanism of resistance, 
not only to FLT3 inhibitors but also to chemotherapy.  FLT3 mutations have been discovered in 
the LSC population, suggesting that mutant-specific FLT3 inhibitors could eliminate LSCs 
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(432).  However, clinical trials have not demonstrated elimination of LSCs in FLT3 inhibitor-
treated patients (433).  One potential reason is the upregulation of numerous survival pathways 
in LSCs, which are not dependent on FLT3 oncogenic signaling (433, 434).  The elimination of 
LSCs is one of the most challenging issues currently facing AML therapy.   
1.4.3.3  Strategies to overcome resistance to FLT3 targeted inhibitors  Several strategies to 
overcoming resistance to FLT3 inhibitors have been developed or are currently under 
investigation.  The most important FLT3 resistance mechanism to overcome is inhibitor 
resistance mutations.  As mentioned previously, novel FLT3 inhibitors that target these 
resistance mutations are under development, including crenolanib, PLX3397, ponatinib, and 
TTT-3002.  Another route being explored for the prevention of inhibitor resistance mutations is 
the development of dual FLT3 inhibitors.  For example, a dual FLT3/CDK4 inhibitor (435) and 
a dual FLT3/AXL inhibitor (436)  are currently in early stage clinical trials.  Both these 
inhibitors reduce the rate of resistance when compared to selective FLT3 inhibitors alone.  
Also under development is a dual FLT3/SYK inhibitor (437).  The potential of using these 
compounds once resistance has arisen or in combination to reduce the rate of resistance holds 
enormous promise for reducing FLT3 inhibitor resistance mutations.   
Combination therapy of a number of different targeted therapies is being explored to find 
the best approach for patients.  As mentioned above, upregulation of compensatory pathways is a 
common mechanism of resistance to FLT3 inhibitors.  However, when FLT3 inhibitors are 
combined with inhibitors that target the compensatory pathways, the AML blasts become 
sensitive to treatment again.  This has been described for the combination of FLT3 inhibitors 
with MEK inhibitors (438), PI3K inhibitors (428), JAK inhibitors (439), mTOR inhibitors (440), 
AKT inhibitors (426), and BH3 mimetics (441). FL upregulation is a problem for the 
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combination of FLT3 inhibitors with chemotherapy as well as monotherapy with FLT3 
inhibitors.  Use of FLT3 inhibitors in the presence of neutralizing FL monoclonal antibodies has 
been suggested as one approach to alleviate this resistance mechanism (442).   
 The stroma of the bone marrow niche provides numerous survival signals for AML cells.  
Several studies are exploring options for targeting the stroma in combination with FLT3 targeted 
inhibitors.  The most advanced studies are using CXCR4 inhibitors to inhibit pro-survival 
signaling through the CXCR4/CXCL12 axis as well as to mobilize AML blasts out of the bone 
marrow (443).  Combination of a CXCR4 inhibitor with sorafenib was more effective at killing 
AML cells in the bone marrow than sorafenib alone.  Importantly, the CXCR4 inhibitor reduced 
the stromal activation of the PI3K and MEK/ERK pathways.  Other stromal targeting agents are 
in their infancy but studies are exploring the targeting of adhesion molecules (444), hypoxia 
(445) and osteoblasts (446), which are dysregulated in the AML bone marrow niche.    
 LSCs are ultimately responsible for the relapse of patients and monotherapy with FLT3 
inhibitors has failed to eliminate these cells.  However, a recent study discovered that 
combination of FLT3 inhibitors with all-trans retinoic acid (ATRA) synergistically induced 
apoptosis in LSCs (447). Bone marrow transplants from combination-treated mice failed to 
engraft into secondary recipients, suggesting the elimination of LSCs.   As described earlier, 
small molecule inhibition of HCK with the compound A-419259, also eliminated LSCs in a 
patient-derived AML xenograft model (338).  However, at the doses used in that study, A-
419259 was also likely to inhibit FLT3 and other Src-family members, suggesting that dual 
targeting of FLT3 and myeloid SFKs may work synergistically to eliminate LSCs.    
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1.5  HYPOTHESIS AND SPECIFIC AIMS 
1.5.1 Hypothesis  
AML is a hematologic malignancy caused by the expansion of immature AML blasts.  Treatment 
outcomes, particularly in the elderly, have improved only minimally in the last 40 years and 
overall survival is approximately 25%.  FLT3-ITD mutations occur in approximately 25% of 
AML patients and have a particularly poor prognosis.  Furthermore, FLT3-ITD mutations are 
more common in elderly patients who are ineligible for high-dose chemotherapy because of the 
significant toxicities associated with the treatment. Novel, less toxic therapies are clearly needed 
for the treatment of FLT3-ITD+ patients.   
 Numerous FLT3 inhibitors have been tested in clinical trials or are still under 
investigation for the treatment of FLT3-ITD+ AML.  However, use of FLT3 inhibitors as single 
agents has produced underwhelming results with only transient clinical responses being 
observed.  The most common mechanism of resistance involves mutations in the kinase domain 
of FLT3 that prevent drug action.  Additionally, compensatory pathway activation either 
spontaneously or with the assistance of the stromal microenvironment occurs in FLT3 inhibitor-
treated patients.  
 FLT3-ITD is known to activate a number of downstream signaling pathways that 
contribute to its oncogenesis.  The major pathways are the PI3K/AKT pathway and the 
RAS/MEK/ERK pathway.  However, a number of recent studies identified a set of tyrosine 
kinases that are activated downstream of FLT3-ITD and individually are essential to FLT3-ITD 
oncogenesis.  These kinases are the myeloid-restricted SFKs (HCK/FGR/LYN), SYK, and FES.  
These tyrosine kinases are essential for the activation of a number of the major pathways 
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downstream of FLT3-ITD, including the PI3K and RAS/MEK/ERK pathway.  Additionally, 
among the SFKs, HCK has been specifically implicated in LSC survival, making it a particularly 
attractive target for the eradication of AML.   
All of the published data presented here suggests that FLT3-ITD is dependent on 
a relatively small set of kinases for downstream signaling.  Targeting FLT3 plus this set of 
kinases could improve the potency of a compound against FLT3-ITD+ cells.  Additionally, recent 
reports have demonstrated that dual inhibitors can reduce the rate of resistance, so an inhibitor 
targeting the complete set of AML-associated tyrosine kinases could potentially provide that 
advantage as well.  Finally, by targeting a set of kinases, multiple pathways are being 
inhibited at one time, possibly reducing the chance of compensatory pathway activation as a 
mechanism of resistance.  I propose, therefore, that the development of a ‘tuned’ kinase 
inhibitor with a selectivity profile favoring FLT3 and its proximal tyrosine kinase signaling 
partners HCK, FGR, LYN, SYK, and FES would increase the potency against FLT3-ITD+ 
AML cells and significantly decrease the rate of resistance.    
1.5.2 Specific Aims 
1.5.2.1 Aim 1: Determine the efficacy of the AML-associated tyrosine kinase inhibitor 
TL02-59 in both in vitro and in vivo models of AML.  FLT3-ITD signaling requires a 
defined subset of downstream tyrosine kinases to propagate its oncogenic signals.  We set out 
to identify a compound that would inhibit FLT3-ITD, and three of the best characterized AML-
associated kinases (HCK, SYK, and FES) to determine if such a compound could be 
identified and if so whether it displayed significant efficacy against AML cell lines and 
patient-derived AML bone marrow cells. Using an in vitro kinase assay and recombinant
FLT3-ITD, HCK, FES and SYK, we screened a small collection of N-phenylbenzamide tyrosine 
kinase inhibitors and identified a compound (‘TL02-59’) that exhibited three-digit nanomolar 
potency against all four of these recombinant AML-related kinases.  Remarkably, the efficacy 
against the FLT3-ITD+ cell line, MV4-11, was in the picomolar range.  All four kinases are 
expressed and active in MV4-11 cells, and all were inhibited by TL02-59 treatment, suggesting 
that the multi-targeted action of the inhibitor is responsible for its potent effect on cell growth.  
To further explore the efficacy of TL02-59, we obtained 26 primary AML bone marrow samples 
(half FLT3-ITD+ and half FLT3-WT).  TL02-59 displayed a wide range of potencies against the 
primary samples ranging from 77 nM to over 3 μM.  Interestingly, the top four most sensitive 
samples were FLT3-WT, but expressed very high levels of HCK, FGR and SYK, supporting a 
role for these kinases as inhibitor targets.  Finally, we explored the efficacy of TL02-59 in a 
mouse xenograft model of AML.  MV4-11 cells were engrafted into immunocompromised mice 
and TL02-59 was give once daily by oral gavage for three weeks.  TL02-59 (10 mg/kg) 
completely eliminated MV4-11 cells from the peripheral blood and spleen, and reduced bone 
marrow engraftment by 60%.  These results were significantly better than those obtained with 
sorafenib treatment which had no effect on bone marrow or spleen engraftment at the same dose.   
1.5.2.2 Aim 2: Investigate the full range of TL02-59 target kinases critical for AML efficacy 
The difference in TL02-59 potency against recombinant target kinases in vitro (3-digit nM) and 
suppression of MV4-11 cell growth (3-digit pM) led us to hypothesize that other targets of 
TL02-59 might be crucial for its efficacy.  To determine the full range of TL02-59 kinase targets 
important for its anti-AML efficacy, we performed a KINOMEscan assay.  We discovered that 
TL02-59 is remarkably selective, targeting only 24 kinases out of the 456 kinases tested.   
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 which of these 24 kinases were critical in AML, we performed transcriptional analysis on RNA 
obtained from our 26 primary AML bone marrow specimens for each of the 24 TL02-59 target 
kinases.  This approach identified 15 target kinases that were consistently expressed.  The relative 
expression of each kinase across the 26 AML samples was then correlated with the growth 
inhibitory IC50 value.  Remarkably, myeloid SFK expression (FGR, HCK, and LYN) correlated 
with inhibitor response, as did SYK expression.  The fact that all three SFKs correlated with 
response led us to wonder if inhibition of the SFKs alone could explain TL02-59 efficacy.  To 
explore this possibility, we tested the SFK inhibitor A-419259 against MV4-11 cells and obtained 
an IC50 value about 30-fold higher than TL02-59.  This suggested TL02-59 had other important 
targets that A-419259 did not inhibit.  To identify these kinases, we then performed a 
KINOMEscan assay on A-419259 and explored kinases that TL02-59 inhibited but A-419259 did 
not.  We identified several kinases including SYK as well as the Ser/Thr kinases p38α, TAOK3, 
and STK10.  SYK and p38α have been linked to AML previously but TAOK3 and STK10 have 
never been explored in this context.  To determine if MV4-11 cell growth was dependent on 
TAOK3 or STK10 expression we performed shRNA knockdown of these two kinases.  
Knockdown of STK10 exhibited no effect on MV4-11 cell growth.  However, knockdown of 
TAOK3 completely abolished MV4-11 cell growth suggesting that this kinase is important for 
TL02-59 efficacy.  In summary, our studies show that the multi-targeted kinase inhibitor TL02-59 
has great promise against AML, especially the subset of cases that express active FLT3 and the 
AML-associated tyrosine kinases SYK, HCK, FGR, LYN, and possibly TAOK3. 
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2.0 POTENT INHIBITION OF FLT3-ITD+ AML CELL GROWTH IN VITRO AND 
IN VIVO BY A SINGLE N-PHENYLBENZAMIDE INHIBITOR TARGETING FLT3, 
FES, SYK AND MYELOID SRC-FAMILY KINASES 
2.1 INTRODUCTION 
Acute myelogenous leukemia (AML), the most common form of leukemia in adults, is a 
hematologic malignancy characterized by the growth of immature myeloid progenitor cells that 
overpopulate the bone marrow and spill over into the peripheral blood (232, 448).  First-line 
treatment for AML is typically cytotoxic chemotherapy that has remained invariant over the last 
forty years, despite significant advancements in our molecular understanding of AML (449, 
450).  As a result, overall survival for most AML patients has remained stagnant, especially for 
patients over 60 years of age who often present with comorbidities that limit the use of intensive 
chemotherapy needed to cure the disease (231, 451).      
Fms-like tyrosine kinase receptor 3 (FLT3) is the most commonly mutated gene in AML, 
with approximately thirty percent of patients presenting with activating mutations at diagnosis 
(452, 453).  Two types of FLT3 mutations commonly occur in AML: internal tandem 
duplications (ITDs) and tyrosine kinase domain point mutations. ITDs are in-frame duplications 
within the juxtamembrane region of the receptor that interfere with kinase downregulation and 
occur in approximately 20-25% of patients (454).  Point mutations are observed in approximately 
5% of patients and often localize to the kinase domain activation loop, inducing an active 
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conformation in the absence of FLT3 ligand (415).  Since constitutively active FLT3 is a 
common driver of AML oncogenesis, many small molecule FLT3 kinase inhibitors have been 
developed for clinical use. First-generation FLT3 inhibitors, such as midostaurin, lestaurtinib, 
and sorafenib, have had somewhat limited efficacy due in part to lack of sustained FLT3 
inhibition in vivo and off-target associated toxicity (404). Second-generation FLT3 inhibitors, 
such as quizartinib and crenolanib, show significantly improved specificity for the FLT3 kinase 
domain and efficacy as single agents.  However, inhibitor resistance, largely through acquired 
mutations in the kinase domain, has limited the clinical utility of second-generation compounds 
(385, 421).        
A growing number of studies have linked FLT3 signaling in AML to downstream non-
receptor tyrosine kinases, including the spleen tyrosine kinase (SYK), the cellular homolog of 
the feline sarcoma oncogene (FES), as well as several members of the Src kinase family 
expressed in myeloid cells (HCK, FGR, and LYN).  SYK interacts directly with FLT3-ITD and 
is essential for c-MYC induction downstream (360, 361).  Genetic knockdown and 
pharmacologic inhibition of SYK have both shown efficacy against AML cells both in vitro and 
in a mouse model.  The Src-family kinase HCK was found to be highly overexpressed in gene 
expression profiles of myeloid leukemia stem cells (LSCs) versus normal hematopoietic stem 
cells (337), suggesting that inhibition of HCK may help eliminate LSC growth.  Subsequent 
work showed that shRNA-knockdown of HCK expression blocked AML cell growth in vitro and 
that a potent ATP-site inhibitor of HCK (RK-20449; previously reported by us as compound A-
419259) (455, 456) dramatically reduced the growth of primary AML cells in engrafted, 
immunocompromised NOD scid gamma (‘NSG’) mice (338).  LYN, another myeloid Src-family 
member, has been identified as active in a majority of clinical AML isolates and has been linked 
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to the activation of STAT5 by FLT3-ITD (333, 335, 336). The Src-family kinase FGR is also 
highly expressed in a subset of FLT3-ITD+ AML samples and selective siRNA knockdown of 
FGR significantly reduced the growth of primary FLT3-ITD+ AML cells (339).  FGR (as well as 
HCK and LYN) has also been shown to have high kinase activity in patient-derived LSCs (339).  
Finally, the FES tyrosine kinase, which is also strongly expressed in normal cells of myeloid 
lineage (457), was reported to be constitutively active in both FLT3-ITD+ AML cell lines and 
patient samples (384).  Selective knockdown of FES using siRNA reduced the growth of FLT3-
ITD+ AML cell lines to a similar extent as knockdown of the FLT3-ITD driver oncogene itself 
(384).  Taken together, these studies strongly suggest that active FLT3 cooperates with multiple 
non-receptor tyrosine kinases in the pathogenesis of AML, and that simultaneous inhibition of 
FLT3 and these AML-associated kinases may confer additional clinical benefit in patients where 
these kinases are expressed and active. 
Here we report the identification of the N-phenylbenzamide tyrosine kinase inhibitor 
TL02-59, which inhibits FLT3 as well as each of the AML-associated kinases described above 
(SYK, FES, HCK, and other Src-family kinases).  Remarkably, TL02-59 inhibited the growth of 
the FLT3-ITD+ cell line MV4-11 with picomolar potency.  Each of these AML-associated 
kinases is expressed and active in this cell line, suggesting that the combined action of TL02-59 
against all of these kinases is responsible for its potent anti-proliferative action.  We also 
explored the efficacy of TL02-59 against a panel of 26 patient-derived AML bone marrow 
samples, and observed a wide range of inhibitory responses spanning nearly two orders of 
magnitude. KINOMEscan analysis of TL02-59 target specificity followed by kinase gene 
expression profiling revealed that expression of the Src-family kinases HCK, FGR, and LYN, as 
well as SYK, were most strongly correlated with the TL02-59 response in primary AML bone 
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marrow.  Several other kinases identified as TL02-59 inhibitor targets by KINOMEscan analysis 
were also strongly expressed in primary AML cells.  One of these kinases, the Ser/Thr kinase 
TAOK3, was confirmed as a TL02-59 inhibitor target in vitro; shRNA knockdown of TAOK3 
resulted in growth suppression of MV4-11 AML cells.  Comparative KINOMEscan profiling of 
TL02-59 vs. A-419259, the previously characterized HCK inhibitor that eliminated AML stem 
cells in vivo, showed a narrower selectivity profile for A-419259 that included FLT3 and Src-
family kinases but not SYK, FES, or TAOK3.  Interestingly, TL02-59 was 30-fold more potent 
than A-419259 against MV4-11 cell proliferation in vitro, strongly suggesting that inhibition of 
these additional kinases contributes to TL02-59 potency.  Finally, TL02-59 efficacy was tested in 
vivo using immunocompromised mice engrafted with MV4-11 cells.  Oral administration of 
TL02-59 at 10 mg/kg for three weeks completely eliminated MV4-11 cells from the spleen and 
peripheral blood, while dramatically suppressing bone marrow involvement.  Altogether, our 
results suggest that compounds like TL02-59, capable of simultaneous inhibition of FLT3 and 
the spectrum of AML-associated kinases defined here, may represent a new generation of 
targeted therapies for a subset of AML patients. TL02-59 is particularly attractive in this regard, 
because its narrow specificity profile is very closely tuned to the kinase activities associated with 
AML, with very few non-AML kinase targets that may hinder clinical development. 
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2.2 RESULTS 
2.2.1  Identification of a small molecule inhibitor of FLT3 and the AML-associated 
tyrosine kinases SYK, FES and the Src-family kinase HCK 
Recent studies have shown that active mutants of FLT3 cooperate with multiple cytoplasmic 
tyrosine kinases to drive AML pathogenesis, including SYK, FES, and the Src-family kinases 
HCK, LYN and FGR (see Introduction).  Genetic knockdown of each kinase results in growth 
arrest and apoptosis of FLT3-ITD+ AML cells, suggesting that an inhibitor targeting FLT3 and 
these AML-associated kinases may potently suppress AML cell growth. To test this idea, we 
evaluated a collection of ten N-phenylbenzamide kinase inhibitors for activity against 
recombinant FLT3-ITD, FES, HCK and SYK kinases in vitro.  The structures of these 
compounds are presented in Figure 4A and Table 4.  We also determined their growth inhibitory 
potency towards the FLT3-ITD+ AML cell line, MV4-11, which has been previously shown to 
express active FES, SYK, HCK and other myeloid Src-family members (337, 338, 360, 361, 
384, 458).  Three compounds (TL02-59, TL8-133, and TL8-187) inhibited FLT3-ITD, FES, 
HCK and SYK with three-digit nanomolar potency in vitro (Table 4).  Remarkably, each of these 
compounds also blocked MV4-11 AML cell growth with an IC50 value of less than 1 nM, 
suggesting that simultaneous inhibition of FLT3-ITD and these associated kinases is responsible 
for their potency.  In contrast, compounds that showed lower potency against FLT3-ITD or any 
of the AML-associated kinases in vitro were also weaker inhibitors of MV4-11 cell growth.  For 
example, compound TL8-143 displayed similar potency against FLT3-ITD and HCK as the top 
three inhibitors, but about 10-fold lower potency against FES and SYK in vitro.  This difference 
translated into significantly reduced cellular potency against MV4-11 cells, with an IC50 value of  
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Compound R-group 
MV4-11 cells 
IC50, nM 
In vitro Kinase Assays (IC50, nM) 
FLT3-ITD FES HCK SYK 
TL02-59 - 0.78 440 290 160 470 
TL8-133 
 
0.46 490 260 360 400 
TL8-187 
 
0.55 710 320 530 670 
TL8-130 
 
9.9 490 180 480 600 
TL8-142  10.8 700 2500 700 160 
TL8-129  27.4 3000 1300 2400 1500 
TL8-139  64.7 3000 880 5300 3520 
TL8-128  77.1 640 320 730 600 
TL9-169  386.5 6400 3000 1410 5300 
TL8-143  1567 570 3200 133 5660 
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Table 4: Screening of TL02-59 and the TL8 analogs. 
TL02-59 and the nine analogs shown were evaluated for their growth inhibitory activity in the FLT3-ITD+ AML cell 
line, MV4-11, using the Cell Titer Blue assay (Promega).  Each compound was also tested for inhibitory activity in 
vitro using recombinant FLT3-ITD, FES, HCK, and SYK kinases and the Z’Lyte kinase assay (Invitrogen).  Results 
from both assays are presented as IC50 values (nM).  The structures of TL02-59 and the related TL8 scaffold are 
shown in Figure 4. 
 
1.6 μM (about 2,000-fold less potent than TL02-59).  This observation strongly supports the idea 
that inhibition of AML-associated kinases in addition to the FLT3-ITD driver may be of 
therapeutic benefit in AML.  Subsequent mechanistic studies focused on TL02-59, because of its 
target kinase spectrum, cellular potency, and favorable pharmacokinetic properties.  The 
synthesis of TL02-59 has been reported previously (analog 8 in Tan, et al.) (459). To determine 
whether TL02-59 was selective for FLT3-ITD+ AML cells, we examined its inhibitory potency 
against the THP-1 myeloid leukemia cell line, which expresses wild-type FLT3. TL02-59 had no 
effect on THP-1 cell proliferation at concentrations as high as 1 μM, with slight growth 
suppression evident at 3 µM (Fig. 4B and data not shown).  TL02-59 also selectively induced 
apoptosis in MV4-11 cells, without affecting THP-1 cells (Fig. 4C), and was a more potent 
inducer of apoptosis than tandutinib, a FLT3 inhibitor previously tested in clinical trials against 
FLT3-ITD+ AML (460). 
We next confirmed that each of the TL02-59 target kinases tested in vitro were expressed 
and active in MV4-11 cells, and that TL02-59 treatment inhibited each of these kinases.  MV4-
11 cells were treated with 100 nM TL02-59 for six hours, and FLT3-ITD, FES, HCK, and SYK 
were immunoprecipitated followed by immunoblotting with anti-phosphotyrosine antibodies.  As  
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Figure 4:  TL02-59 inhibits the growth and induces apoptosis in the FLT3-ITD+ AML cell line, MV4-11. 
A) The chemical structure of TL02-59 and the TL8 series N-phenylbenzaminde scaffold; R groups are shown in 
Table 1. B) Growth inhibition was measured using the Cell Titer Blue viability assay (Promega) by incubating each 
cell line over a range of TL02-59 concentrations for 72 hours.  For THP-1 cells, additional concentrations up to 3.0 
µM did not inhibit growth (not shown).  C) MV4-11 and THP-1 AML cells were incubated with tandutinib (100 
nM), TL02-59 (100 nM), staurosporine (1 µM) or the DMSO carrier solvent for 72 hours.  Apoptosis measured 
using the Apo-ONE Homogeneous Caspase 3/7 Assay (Promega), and cell viability was measure using the Cell 
Titer Blue assay.  Results are present as mean ratios of caspase activity to viability from three independent 
experiments ± SD.  D) Inhibition of endogenous TL02-59 target kinases in MV4-11 cells.  Cells were treated with 
100 nM TL02-59 for six hours, lysed, and each of kinases shown was immunoprecipitated.  For FLT3 and SYK, the 
immunoprecipitates were blotted with the antiphosphotyrosine antibody, pY99.  For HCK and FES, phosphospecific 
antibodies against the activation loop phosphotyrosine were used (pY418 and pY713, respectively).  Aliquots of 
each immunoprecipiate were also blotted for kinase protein to ensure equal loading. 
 
shown in Figure 4D, all four kinases were present and active in MV4-11 cells, and TL02-59 
treatment inhibited their autophosphorylation, consistent with the in vitro kinase assays. 
2.2.2 KINOMEscan analysis coupled to primary AML cell kinase expression profiling 
reveals additional targets for TL02-59 
The remarkable potency of TL02-59 toward MV4-11 cells led us to define the complete range of 
kinase targets for this compound in AML.  First, we performed KINOMEscan analysis, a broad 
spectrum competition binding assay for determining ATP-site inhibitor specificity across almost 
the entire kinome (461).  We profiled TL02-59 against 456 kinases that cover all eight kinase 
subfamilies at the relatively high concentration of 1 μM, which is about 2- to 6-fold higher than 
the in vitro IC50 values for inhibition of the known target kinases and more than 1,000-fold 
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Figure 5: KINOMEscan analysis of TL02-59 and A-419259. 
To assess the spectrum of possible kinase targets, TL02-59 and A-419259 were profiled at 1 μM against 456 and 
468 kinases, respectively, using the KINOMEscan screening assay (DiscoverRx).  Results are presented as circular 
kinase dendrograms, produced using the program TREEspot (DiscoverRx).  The circle size represents the relative 
binding score for each kinase, with a larger circle size indicating tighter binding.  Kinases that are not inhibitor 
targets are represented by the small green spots.  Only kinases with a binding score of ˂ 1% relative to the DMSO 
control are shown.  The specificity (S) score represents the fraction of target kinases within the 1% cutoff relative to 
the total number screened.  The identity of the positive hits from this analysis are shown in Table 7 of the main text. 
 
higher than the IC50 value for growth suppression of MV4-11 cells (Table 4).  TL02-59 was 
remarkably selective in the KINOMEscan assay, interacting with only twenty-four kinases out of 
the 456 tested for a selectivity (S) score of 0.07 (Fig. 5 and Table 7).  The majority of the   
TL02-59 
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24 Interactions Mapped   
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interacting kinases are members of the tyrosine kinase and tyrosine kinase-like families, and 
include FLT3 (wild-type and ITD), HCK, SYK, and FES, consistent with our in vitro kinase 
assay data (Table 4).  Other potential tyrosine kinase targets for TL02-59 include the FLT3-
related kinase c-KIT and the additional Src-family members LYN, BLK and LCK as well as 
SRC itself.  The remainder of the positive interactions mapped to members of the STE [TAOK2, 
TAOK3/JIK, SLK, STK10/LOK, MAP4K2) and CMGC (p38α, JNK2) Ser/Thr kinase families.  
While p38α has been linked to AML in several previous studies (462-465), the remaining 
Ser/Thr kinases have no known role in AML. 
To define the subset of potential target kinases for TL02-59 identified by KINOMEscan 
that are relevant to AML, we next determined the expression profile of all TL02-59 
KINOMEscan hits in a set of bone marrow specimens from 26 AML patients.  The clinical 
characteristics and cytogenetic profiles of our AML patient cohort are presented in Table 5.  We 
first determined the FLT3 genotype of each patient by PCR of genomic DNA and sequence 
analysis. Thirteen samples carried an ITD in one FLT3 allele, while the remaining thirteen 
patients were wild-type for FLT3 (Table 6).  Using quantitative real-time RT-PCR (qPCR), we 
next profiled the relative expression of all 24 of the TL02-59 target kinases plus three additional 
members of the Src-kinase family that were very close to the specificity cut-off in the 
KINOMEscan analysis (FGR, FYN, YES).  A relative expression value was calculated for each 
kinase as the base 2 antilog of the difference in qPCR Ct value for the GAPDH reference gene 
and the Ct value for each kinase.  Each value was then normalized to the mean expression value 
for all 27 TL02-59 target kinases analyzed in each individual sample to create an expression 
profile for each patient (Figure 6).  Using this approach, we found that 15 of the 27 target kinases 
for TL02-59 identified by KINOMEscan analysis showed relative expression values greater than  
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Patient Age Gender FAB Cytogenetics FLT3 status 
% Blasts 
(PB) 
% Blasts 
(BM) 
047 47 F M4 t(6,9)(p23;34) ITD 14 59 
051 68 M M2 Normal WT 54 59 
069 30 F M5a t(11;19)(q23;p13.3), +19 WT 50 87 
078 41 F M4Eo -7,inv(16)(p13.1q22) WT 49 66 
079 51 M NA Normal ITD 24 42 
080 43 F NA t(9;11)(p22;q23) WT 70 92 
093 47 M M4 inv(16)(p13.1q22) WT 58 54 
104 66 F M1 Normal ITD 86 92 
175 74 F NA Normal ITD 98 95 
194 64 F M5 t(6,11)(q27;q23) ITD 20 74 
196 71 F NA add(12)(p13) WT 17 46 
239 47 M M4 inv(16)(p13.1q22) WT 66 71 
289 70 M NA Normal ITD 62 70 
332 46 M M4 Normal ITD 83 86 
397 77 M M4 Normal WT 18 48 
410 54 M NA Normal ITD 74 79 
419 72 F NA Complex WT 4 78 
451 51 F NA Complex WT 92 90 
453 66 M M5a t(9;11)(p22;q23) WT 87 96 
454 69 F NA Complex ITD 44 53 
465 54 F NA +8 WT 25 60 
488 82 M NA Normal ITD 21 65 
490 65 M NA t(2;12)(p13;p13) ITD 83 96 
505 53 F NA Normal WT 88 96 
515 48 F NA Normal ITD 90 72 
548 69 F NA Normal ITD 86 96 
 
Table 5. Clinical characteristics of primary AML bone marrow samples. 
Patient gender, age at diagnosis and French-American-British (FAB) AML classification is shown.  FLT3 status is 
defined as wild-type (WT) or internal tandem duplication (ITD); N/A, not available.  Percent of leukemic blast cells 
present in peripheral blood (PB) and bone marrow (BM) are also shown.  Samples are listed in order of ascending 
case number. 
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2 in at least four of the FLT3-ITD+ bone marrow samples (Fig. 6A).  All of the kinase targets for 
TL02-59 previously confirmed by in vitro kinase assay (FLT3, FES, HCK and SYK) were highly 
expressed in the FLT3-ITD+ samples.  Remarkably, a very similar pattern of kinase gene 
expression was observed in patient AML samples wild-type for FLT3, with the same group of 15 
kinases showing relative expression values greater than 2 in at least four samples (Fig. 6B).  The 
most highly expressed kinase in the FLT3-ITD+ samples is FGR, a Src-family kinase with 
myeloid-restricted expression.  High levels of FGR expression were observed in 8 of 13 samples, 
with much lower expression in the remaining cases.  A similar bimodal FGR expression pattern 
was mirrored in the AML samples wild-type for FLT3, where FGR was among the most highly 
expressed protein kinases. 
We next evaluated whether the pattern of relative TL02-59 target kinase expression in 
our cohort of primary AML bone marrow samples is representative of the larger AML 
population.  To do this, TL02-59 target kinase gene expression values (determined by RNAseq 
analysis) from AML specimens with wild-type (n = 111) or ITD (n = 34) forms of FLT3 were 
download from the TCGA database (51) and normalized to the average expression across all 27 
target kinases for TL02-59 within each sample as per our qPCR data.  The average of the 
normalized expression values for each kinase from the TCGA database were then plotted against 
the average values obtained for each kinase by qPCR in our AML cohort for the FLT3-ITD and 
FLT3-WT AML populations (Fig. 7).  A strong linear correlation was observed between the two 
data sets, indicating that the relative TL02-59 target kinase expression pattern observed in our 
primary AML bone marrow samples is mirrored in this larger population of AML specimens.    
We also performed qPCR-based expression profiling for the same set of TL02-59 target 
kinases using RNA isolated from the FLT3-ITD+ MV4-11 AML cell line, which is remarkably 
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Figure 6: Expression of TL02-59 target kinases in primary AML bone marrow samples. 
Expression of the 27 putative TL02-59 target kinases identified by KINOMEscan analysis was determined in 26 
primary AML bone marrow samples by qPCR.  Relative expression values were calculated as the base 2 antilog of 
the difference in qPCR Ct values for the GAPDH reference gene and the Ct value for each kinase.  The resulting 
expression values were then plotted as a distribution relative to the mean value for all 27 kinases analyzed in each 
individual patient sample.  All determinations were made on at least two independent RNA samples from each 
patient. Each patient is represented by a dot. FLT3 status was determined for each patient by PCR and sequencing 
(Table 6) and results are grouped as FLT3-ITD (panel A) or FLT3-WT (panel B; n=13 in each case). 
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sensitive to this multi-targeted kinase inhibitor.  The relative expression value for each kinase in 
MV4-11 cells was then plotted against the average expression value for each kinase across the 
FLT3-ITD+ primary AML samples (Fig. 8A) and those expressing wild-type FLT3 (Fig. 8B).  In 
both cases, we observed a strong positive correlation between TL02-59 target kinase expression 
  
Figure 7: Comparison of TL02-59 target kinase expression in primary AML samples from the TCGA 
database vs. primary AML bone marrow samples from this study. 
Comparison of TL02-59 target kinase expression in primary AML samples from the TCGA database vs. primary 
AML bone marrow samples from this study. TL02-59 target kinase RNAseq expression data were downloaded as 
FPKM values (see Garber et al. Nature Methods 8: 469, 2011) from the TCGA database (see Garber et al. Nature 
Methods 8: 469, 2011) and normalized to the average expression across all 27 kinases within each sample.  Average 
values for each kinase from the TCGA database (FLT3-ITD: n = 34, FLT3-WT: n =111) were plotted against the 
average values obtained for each kinase by qPCR in this study for FLT3-ITD (n = 13; A) and FLT3-WT (n = 12; B) 
primary AML bone marrow samples. Data were analyzed by linear regression and the best-fit line and 95% 
confidence intervals are shown; p < 0.0001 in both cases.   
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in MV4-11 cells and primary AML samples, validating MV4-11 cells as a model for testing 
TL02-59 and the related kinase inhibitors shown in Table 4.  One notable outlier in this analysis 
is FGR, which is strongly expressed in a majority of FLT3-ITD+ primary bone marrow 
specimens relative to MV4-11 cells.  In primary AML samples wild-type for FLT3, both FGR 
and c-KIT are more highly expressed in primary AML compared to MV4-11 cells.   
2.2.3 Sensitivity of primary AML bone marrow samples to TL02-59 treatment correlates 
with AML tyrosine kinase expression 
We next explored the sensitivity of primary AML bone marrow samples to growth arrest in 
response to TL02-59 treatment.  Primary AML bone marrow samples were cultured on 
mitotically inactive HS-27 feeder fibroblasts in the presence of the myeloid cytokines IL-3, IL-6, 
and SCF according to the method of Klco et al. (466).  This approach allowed all of the primary 
cells to survive ex vivo and expand in number for about one week.  Cultures were then 
established in the presence of a range of TL02-59 concentrations, and IC50 values for growth 
inhibition were determined using the Cell Titer Blue cell viability assay (see Methods).  As 
shown in Table 6, the primary AML bone marrow samples showed a remarkable range of 
sensitivity to this kinase inhibitor, ranging from 77 nM to greater than 3000 nM.  We then looked 
for statistical correlations between TL02-59 sensitivity and relative expression values for each of  
 the TL02-59 target kinases present in the AML bone marrow specimens.  As shown in Figure 9, 
relative expression levels of the three myeloid Src-family kinases (FGR, HCK and LYN) showed 
a significant inverse correlation with the IC50 values for TL02-59 across the 26 AML samples.  
SYK expression also significantly correlated with the inhibitor response, supporting a role for 
this kinase as a key TL02-59 target kinase as well.  FES expression also showed a similar trend 
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with inhibitor sensitivity that did not reach statistical significance, which may reflect the 
relatively small patient sample size.  
 
Figure 8: Comparison of TL02-59 target kinase expression in FLT3-ITD+ MV4-11 AML cells vs. 
primary AML bone marrow samples. 
Comparison of TL02-59 target kinase expression in FLT3-ITD+ MV4-11 AML cells vs. primary AML bone marrow 
samples.  The TL02-59 target kinase expression profile in MV4-11 cells was determined by qPCR as described in 
the Methods section, and the relative expression values were plotted against the average values obtained for each 
kinase in the FLT3-ITD (n = 13; A) and FLT3-WT (n = 13; B) primary AML bone marrow samples.  Data were 
analyzed by linear regression; the best-fit line and 95% confidence intervals are shown; p < 0.0001 in both cases.  
Outliers included the Src-family kinase FGR, which is strongly expressed in primary AML cells, as well as c-KIT 
which is strongly expressed in primary cells that are wild-type for FLT3. 
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2.2.4 Inhibition of Src-family kinases alone does not account for TL02-59 potency 
Kinase expression profiling and correlation analyses presented in the previous sections strongly 
implicate members of the Src kinase family, especially FGR, HCK and LYN, as key targets for 
TL02-59 action in AML cells.  To explore this question directly, we turned to the 
pyrrolopyrimidine compound A-419259, a potent cell-active inhibitor of HCK and other Src-
family kinases (455, 456).  Previous studies have shown that treatment with A-419259 (also 
referenced as RK-20449 in the literature; see Fig. 10A for structure) dramatically reduced the 
growth of primary AML cells in engrafted immunocompromised mice, an outcome attributed to 
inhibition of HCK which is highly expressed in AML-derived leukemic stem cells (338).  
KINOMEscan analysis revealed a target specificity profile for A-419259 even narrower than that 
of TL02-59, with only 19 interactions observed out of 468 kinases tested for a selectivity score 
of 0.05 (Fig. 5 and Table 7).  In addition to HCK, FGR, and other Src-family kinases, A-419259 
also interacted with FLT3-ITD in the KINOMEscan assay, but not with FES or SYK, two other 
important targets for TL02-59.  This observation suggested that A-419259 may serve as a useful 
tool compound to ask whether inhibition of FLT3-ITD plus Src-family kinases is sufficient to 
explain the remarkable potency of TL02-59 in MV4-11 cells or whether other kinases play a 
role.  As shown in Figure 10B, MV4-11 cell growth was inhibited by A-419259 with an IC50 
value of 37 nM, which is about 30-fold higher than that observed for TL02-59.  This difference 
in potency suggests that additional target kinases contribute to TL02-59 efficacy. 
 To identify additional kinases that contribute to the TL02-59 sensitivity of AML cells, we 
compared the KINOMEscan profiles for both compounds against each of the TL02-59 target 
kinases expressed in our primary AML samples.  This comparison identified several candidate 
kinase targets unique to TL02-59 and already implicated in FLT3-ITD+ AML (SYK, FES, and  
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Patient 
FLT3 
Status 
ITD sequence 
TL02-59 Sensitivity 
(IC50, nM) 
451 wild-type N/A 77 
453 wild-type N/A 88 
196 wild-type N/A 119 
051 wild-type N/A 185 
454 ITD N.D. 229 
488 ITD GSSDNEYFYVDFREYE 330 
332 ITD YDLKWEVTGSSDNGYFYVDFREYE 403 
465 wild-type N/A 408 
079 ITD YDLKWEVTGSSDNEYFYVDFREYE 477 
548 ITD YDLKWEFPRENLGPYVDFREYE 559 
080 wild-type N/A 635 
078 wild-type N/A 663 
239 wild-type N/A 698 
047 ITD N.D. 701 
397 wild-type N/A 767 
194 ITD N.D. 806 
410 ITD YDLKWEFPRKNEYFYVDFREYE 814 
490 ITD N.D. 891 
419 wild-type N/A 1113 
289 ITD 
YDRAGSSDNEYFYVDFREYE/ 
YDLKWEVTGSSDNEYFYADFREYE 
1420 
515 ITD YDLKWEFPRENLEQGKQVTGSSDNEYFYVDFREYE 1887 
093 wild-type N/A 2660 
505 wild-type N/A >3000 
175 ITD YVLKWEFPRGEMVQVTGSSDNEYFYVDFREYE >3000 
104 ITD VDFREYE >3000 
069 wild-type N/A N/A 
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Table 6:  FLT3 genotype and TL02-59 sensitivity of primary AML bone marrow cells.  
Genomic DNA was isolated from 27 AML patients and a portion of the FLT3 kinase domain coding region was 
amplified by PCR.  Thirteen of the samples showed internal tandem duplications (ITDs) within the kinase domain 
juxtamembrane coding region of one FLT3 allele.  DNA sequence analysis revealed the ITD amino acid sequences 
of 9 out of 13 samples as shown.  Primary cells were then cultured in vitro on fibroblast feeder layers in the presence 
of IL-3, IL-6, and SCF over a range of TL02-59 concentrations.  Viable cell outgrowth was determined by Cell Titer 
Blue assay and the IC50 values shown were calculated by non-linear curve fitting of the resulting concentration-
response curves.  Samples are listed in ascending order of TL02-59 sensitivity.  N/A, not applicable; N.D., ITD 
present by PCR but sequence could not be determined. 
 
p38α) as well as several others not previously examined in the context of AML (STK10, 
TAO2/3, MAP4K2 and SLK; Table 7).  To validate the KINOMEscan result, we performed in 
vitro kinase assays with recombinant SYK, FES, TAOK3, p38α, as well as FGR.  As shown in 
Figure11, SYK, FES, TAOK3 and p38α were all inhibited by TL02-59 in the mid-nanomolar 
range, with much lower sensitivity to A-419259.  These findings suggest that in addition to FLT3 
and myeloid Src-family kinases, inhibition of FES, SYK, p38α and TAOK3 may also contribute 
to TL02-59 efficacy in MV4-11 cells and in primary AML bone marrow.  We also tested both 
kinase inhibitors against FGR, the kinase most highly correlated with TL02-59 sensitivity in our 
primary AML bone marrow samples. To our surprise, FGR was inhibited by both compounds in 
the low picomolar range, identifying it as the most sensitive kinase tested in vitro.  Note that 
previous studies have shown that the Ser/Thr kinase MAP4K2 is potently inhibited by TL02-59 
as well, suggesting that inhibition of this kinase may also contribute to AML sensitivity to this 
inhibitor (459).  KINOMEscan and AML kinase expression profiling data presented above 
implicated the Ser/Thr kinases TAOK3 and STK10 as contributors to the AML phenotype and as 
potential TL02-59 inhibitor targets.  To independently explore the role of TAOK3 and STK10 in 
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AML, we performed lentiviral shRNA knockdown studies targeting each of these kinases in 
MV4-11 cells. We also targeted FGR by this approach, because of its high-level of expression in 
a subset of primary AML bone marrow cells.  HCK was included as a positive control, because 
previous studies have shown that knockdown of HCK expression reduces the growth of MV4-11  
 
 
Figure 9: Myeloid-restricted Src-family kinases and SYK significantly correlate with TL02-59 
sensitivity in patient AML bone marrow samples.  
Relative TL02-59 target kinase expression (from Figure 6) was correlated with TL02-59 IC50 values determined for 
each of the primary AML bone marrow samples (Table 6).  Spearman’s correlations were calculated for each kinase 
across all of the AML samples, and the resulting correlation coefficients are plotted in ascending order. Blue bars 
represent kinases that show a significant negative correlation with TL02-59 IC50 values with p < 0.05; green bars 
represent p < 0.1. Grey bars represent kinases that did not reach statistical significance 
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 Figure 10: The Src-family kinase inhibitor A-419259 is less potent than TL02-59 against MV4-11 AML cells. 
A) Chemical structure of the pyrrolopyrimidine Src-family kinase inhibitor A-419259, also known as RK-20449. B) 
MV4-11 cells were incubated over the range of inhibitor concentrations shown for 72 hours and viability was 
assessed by Cell Titer Blue assay.  Curves were fit by non-linear regression and yielded the IC50 values shown. 
 
cells (337, 338).  For these experiments, MV4-11 cells were infected with equivalent amounts of 
virus and growth was monitored over the course of six days (Fig. 12A and B).  Cells infected 
with virus expressing GFP served as the reference control. The efficacy of target kinase 
knockdown was determined in parallel for each infected cell population by qPCR (Fig. 12C). As 
shown in Figure 12A, both lentiviral shRNAs targeting FGR resulted in significant growth 
suppression, consistent with the ~ 50% reduction in FGR mRNA levels observed by qPCR (Fig. 
12C).  For HCK, efficient lentiviral knockdown was achieved with one of the two shRNAs tested 
and this also resulted in significant growth arrest.  A similar result was observed with TAOK3, in 
which more efficient shRNA knockdown resulted in almost complete growth suppression, while 
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TL02-59 
Kinase Target 
KINOMEscan 
Percent residual binding at 1.0 µM inhibitor 
TL02-59 A-419259 
FGR 2.3 0.85 
SYK 1.2 100 
FLT3 0.6 0.65 
HCK 0.3 1.9 
p38α 0 100 
LYN 1 1.7 
STK10 0 20 
TAOK3 0.3 100 
c-KIT 2.2 0.15 
SLK 0.8 100 
ABL1 0.2 0.25 
MAP4K2 0.25 98 
FYN 23 5.1 
FES 0.75 100 
TAOK2 0.1 85 
SRC 1 0.1 
YES 5.8 0 
 
Table 7: TL02-59 target kinases expressed in MV4-11 AML cells and primary FLT3-ITD+ AML blasts show 
differential sensitivity to A-419259. 
Putative TL02-59 kinase inhibitor targets identified in the KINOMEscan assay and expressed in primary FLT3-ITD+ 
AML blasts are listed, together with their responses in the KINOMEscan assay.  Values represent percent of residual 
kinase binding to the immobilized probe at an inhibitor concentration 1.0 µM (e.g. a value of zero equals 100% 
probe displacement, while a value of 100 equals no binding of test compound to the target kinase). Kinases are 
shown in rank order of their relative expression in FLT3-ITD+ primary AML bone marrow samples. The highlighted 
rows show at least 80-fold selectivity for TL02-59 vs. A-419259. 
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less efficient knockdown was without effect.  Finally, a single shRNA targeting STK10 resulted 
in an 85% suppression of mRNA levels for this kinase, but did not significantly influence cell 
growth.  Altogether, these results link TAOK3 to AML pathogenesis for the first time, and 
suggest that inhibition of TAOK3 kinase activity contributes to the efficacy of TL02-59 in MV4-
11 cells as well as primary AML bone marrow cells, in which it is consistently expressed at 
relatively high levels. 
2.2.5 TL02-59 is an orally active inhibitor of AML in vivo 
Studies presented above demonstrate that TL02-59 is an effective inhibitor of AML-derived cell 
lines and primary bone marrow samples, and that its kinase inhibitor target profile closely 
matches the spectrum of kinases commonly expressed in many AML patients.  Pharmacokinetic 
studies in mice demonstrated the TL02-59 is orally bioavailable and displays a plasma half-life 
of about 6 hours, making it an attractive candidate for in vivo evaluation (data not shown).  To 
test the efficacy of TL02-59 in vivo, we turned to an MV4-11 AML cell xenograft model based 
on NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) immunocompromised mice. A recent study 
demonstrated that tail vein injection of NSG mice with MV4-11 cells leads to rapid engraftment 
of the bone marrow and spleen, providing a rigorous model to test TL02-59 efficacy in vivo 
(466). 
 For our studies, cohorts of NSG mice were injected with MV4-11 cells through the tail 
vein, and allowed to engraft for two weeks.  After the engraftment period, mice were treated 
daily by oral gavage with TL02-59 at 1 and 10 mg/kg, the FDA-approved FLT3 inhibitor 
sorafenib (10 mg/kg) as a basis of comparison, or vehicle alone for three weeks.  At the end of 
the study, the presence of MV4-11 cells in the bone marrow, spleen, and peripheral blood was  
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Figure 11:  A subset of TL02-59 target kinases show differential sensitivity to TL02-59 and A-419259 in vitro. 
Recombinant FGR, SYK, TAOK3, p38α, and FES were tested for inhibitor sensitivity in the Z’LYTE in vitro kinase 
assay with the ATP concentration set to the Km value for each kinase.  IC50 values (nM) were calculated by non-
linear regression analysis of the resulting dose-response curves using GraphPad Prism, and are summarized in the 
table. 
 
assessed by flow cytometry using antibodies specific for human CD45+ and CD33+ both of 
which are expressed on the surface of MV4-11 cells (Figs. 13A and B).  Three weeks of TL02-
59 treatment at 1 mg/kg reduced bone marrow engraftment of MV4-11 cells by 20%, reduced 
spleen engraftment by half while suppressing levels of leukemia cells in the peripheral blood by 
70%. At 10 mg/kg, TL02-59 treatment resulted in a 60% reduction in bone marrow engraftment 
of MV4-11 cells, with complete eradication of leukemic cells from the spleen and peripheral 
blood. On the other hand, three weeks of sorafenib treatment at 10 mg/kg had no effect on either 
bone marrow or spleen engraftment of MV4-11 cells, although a significant reduction of 
leukemic cell counts in the peripheral blood was observed. Histopathological examination of 
both the spleen and the bone marrow from each of the treatment groups supports the flow 
cytometry results. Thin sections from all five groups were stained with antibodies to human 
CD45 and are presented in Figure 13C. Bone marrow sections from mice receiving MV4-11 
cells alone show heavy infiltration of MV4-11 cells. Treatment with TL02-59 at the higher dose 
restored the normal bone marrow architecture, although some MV4-11 cells are still evident. 
Spleen sections from mice treated with TL02-59 at 10 mg/kg were completely devoid of MV4-
11 cells. In contrast, spleen and bone marrow sections from animals treated with sorafenib at 10 
mg/kg still stained strongly for MV4-11 cells in a manner indistinguishable from the vehicle 
controls   
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Figure 12:  shRNA knockdown of TL02-59 target kinases reduces the growth of MV4-11 cells.  
MV4-11 cells were infected with lentiviruses containing shRNAs targeting HCK, FGR (panel A), STK10 or 
TAOK3 (panel B) and cell growth was measured daily for the next six days using the Cell Titer Blue assay.  Control 
cells were infected with a GFP lentivirus as a marker for infection efficiency.  Asterisks indicate significant 
differences (p < 0.05).  C) RNA was isolated 72 hours post-infection and relative kinase expression levels were 
determined by qPCR to determine the effectiveness of the shRNA knockdown relative to the GFP controls. The 
entire study was performed in duplicate, with each data point measured in triplicate.  Mean values are shown ± SD. 
2.3 DISCUSSION 
Here we report the identification of a unique N-phenylbenzamide tyrosine kinase inhibitor, 
TL02-59, with potent growth inhibitory activity against AML both in vitro and in vivo. By 
combining KINOMEscan analysis, in vitro kinase assays and kinase gene expression profiling of 
primary AML bone marrow samples, we defined a consistent pattern of AML-associated kinases 
as key kinase targets for this inhibitor.  In addition to FLT3, these target kinases include SYK, 
the myeloid Src-family kinases FGR, HCK and LYN, as well as FES.  Several Ser/Thr kinases 
were also linked to TL02-59 action, including p38α and TAOK3; the latter kinase has not been 
previously linked to AML. TL02-59 is orally bioavailable and induced substantial reductions in 
splenic and bone marrow engraftment of human FLT3-ITD+ AML cells in NSG mice in response 
to short-term drug exposure with limited toxicity, identifying this multi-kinase inhibitor as a 
promising scaffold for clinical development. 
TL02-59 showed picomolar inhibitory activity against the FLT3-ITD+ AML cell line MV4-11 in 
vitro, consistent with our observation that these cells express active FLT3 as well as all of the 
AML-associated TL02-59 kinase targets found in primary AML cells.  In primary AML bone  
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Figure 13:  TL02-59 reduces MV4-11 cell engraftment in an AML mouse model. 
Human FLT3-ITD+ MV4-11 AML cells were injected into the tail vein of immunocompromised (NSG) mice and 
allowed to engraft for two weeks.  Mice were then treated daily by oral gavage with TL02-59 (1 and 10 mg/kg), 
sorafenib (10 mg/kg), or vehicle. Two mice were not engrafted with MV4-11 cells and received no treatment for use 
as baseline controls.  Following three weeks of treatment, the animals were sacrificed and the presence of MV4-11 
cells in the bone marrow, spleen and peripheral blood were assayed by flow cytometry.  A) Representative flow 
cytometry diagrams for a single mouse within each treatment group.  For the bone marrow and spleen, the inset 
number represents the percentage of human CD45+/CD33+ MV4-11 leukemia cells present.  For whole blood, the 
number of MV4-11 cells present per 25 μL of blood is shown.  B) Summary of all results, where each dot represents 
a single mouse.  For the bone marrow and spleen samples each mouse is plotted as the percentage of human 
CD45+/CD33+ cells present, while blood samples are represented as the number of MV4-11 cells found per 25 μL.  
Horizontal bars indicate the mean value in each group +/- SD. Statistical significance was determined by pairwise 
Student’s t-test, with p values indicated for significantly different groups; ns, not significant. C) Representative thin 
sections of spleen and bone marrow from all five treatment groups.  MV4-11 AML cells were visualized in the 
sections by immunohistochemistry with an antibody specific for human CD45.   
 
marrow samples, however, we observed a wide range of inhibitor responses that were not linked 
to FLT3 mutational status.  In fact, the four most sensitive primary AML bone marrow samples 
were wild-type for FLT3.  However, these TL02-59 sensitive cells expressed the highest overall 
levels of HCK, FGR, SYK, FES, and p38α, all of which have been independently linked to 
AML, as well as TAOK3, which we validate here as a TL02-59 target by shRNA silencing.  In 
contrast, primary AML bone marrow samples that were not sensitive to TL02-59 treatment in 
vitro expressed low levels of the TL02-59 target kinases, regardless of their FLT3 mutational 
status. These observations suggest that the simultaneous action of TL02-59 against this group of 
AML-related target kinases is responsible for its remarkably potent action in MV4-11 cells as 
well as the most sensitive primary AML bone marrow specimens.  By extension, simple qPCR-
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based analysis of the TL02-59 target kinase expression pattern such as the one presented here 
may be a powerful prognostic tool for patient responses to this inhibitor.  Furthermore, our 
results predict that TL02-59 may be efficacious against AML samples with diverse cytogenetic 
backgrounds, provided that they express this key group of AML-associated kinase activities. 
 While the majority of the primary AML bone marrow samples exhibited growth arrest in 
response to TL02-59 treatment in vitro, their sensitivity to this inhibitor was less than that of the 
FLT3-ITD+ AML cell line, MV4-11.  This difference in sensitivity can be attributed to several 
important differences between the cells and the methods used to culture them in vitro.  First, 
while MV4-11 cells express the complete spectrum of known kinase targets for TL02-59, the 
pattern of AML-related kinase expression varies greatly among the primary AML samples (Fig. 
6).  Primary AML cells often carry additional genetic changes that contribute to the leukemic 
phenotype but are not necessarily linked to TL02-59-sensitive kinase pathways (25, 26).  Second, 
primary AML bone marrow samples require culture on fibroblast feeder cells in the presence of a  
cocktail of hematopoietic cytokines, while MV4-11 cells do not.  These culture conditions, 
which mimic the bone marrow niche to some extent, provide additional growth and survival 
signals not present in the MV4-11 cell cultures.  Indeed, culture of MV4-11 cells on fibroblast 
feeders plus cytokines reduces the TL02-59 IC50 value by about 10-fold, supporting this idea 
(data not shown).      
Several previous studies have investigated the role of Src-family kinases in AML, with a 
particular emphasis on HCK.  Important clues pointing to a role for HCK in AML pathogenesis 
originally came from comparative gene expression profiling, which showed that HCK is highly 
overrepresented in primary AML stem cells relative to normal hematopoietic stem cells (337).  
More recently, selective shRNA-knockdown of HCK was shown to block AML cell growth in 
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vitro (338).  Furthermore, the potent ATP-site inhibitor A-419259 (referred to as RK-20449 in 
this prior work) dramatically reduced the growth of primary AML cells in engrafted NSG mice, 
including AML cells derived from patients with acquired resistance to conventional AML 
chemotherapy (338).  These results validate HCK as a kinase inhibitor target in AML, and 
suggest that compounds with activity against HCK may help to eliminate the leukemia stem cell 
population and reduce the risk of relapse.  KINOMEscan data presented here show that A-
419259 also has the potential to inhibit FLT3 as well as other members of the Src kinase family 
expressed in primary AML bone marrow including FGR, FYN and LYN.  Indeed, in vitro kinase 
assays showed that A-419259 (as well as TL02-59) is a picomolar inhibitor of FGR (Fig. 11).  
Thus the efficacy of A-419259 in the patient-derived AML xenograft mouse model (338) is 
likely to result from inhibition of multiple kinase targets, not just HCK.  Interestingly, A-419259 
was less potent then TL02-59 against MV4-11 AML cell proliferation in vitro, suggesting that 
extension of the selectivity profile to include FES, SYK as well as the Ser/Thr kinases p38α and 
TAOK3, adds additional efficacy to the multi-targeted kinase inhibitor approach.   
Our observation that the Ser/Thr kinase TAOK3 is a target for TL02-59 and that shRNA 
knockdown of this kinase induces MV4-11 cell growth arrest implicates this kinase in AML for 
the first time.  Previous studies have linked TAOK3 to stress-activated protein kinase pathways, 
providing a possible link to other kinases implicated in AML.  TAOK3 may be important for the 
activation of p38α following genotoxic insult, because siRNA knockdown of TAOK3 prevented 
activation of p38α and the downstream anti-apoptotic stress response following DNA damage 
(467).  Inhibition of the p38α stress response may also bolster cellular sensitivity to other 
chemotherapeutic agents used in AML.  For example, inhibition of p38α increases the cellular 
response to both all-trans retinoic acid (462) and arsenic trioxide (468, 469).  TAOK3 has also 
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been linked to the inhibition of JNK, which promotes a pro-apoptotic response to genotoxic 
stress (470-472); inhibition of TAOK3 may therefore enhance the pro-apoptotic signal from 
JNK.  Interestingly, RNAi screens for modulators of TRAIL-induced apoptosis (473) and 
chemoresistance (474) both identified TAOK3 as a negative regulator of apoptosis; in both 
studies, RNAi knockdown of TAOK3 increased apoptosis.  These findings are consistent with 
our observation that shRNA-mediated knockdown of TAOK3 by more than 50% resulted in 
growth arrest of MV4-11 cells, and suggest that inhibition of TAOK3 by TL02-59 may 
contribute to the efficacy of this inhibitor.  These observations raise the possibility that TL02-59 
may synergize with existing AML drugs to induce apoptosis.   
While many FLT3 inhibitors have been tested in clinical trials, none have produced 
durable responses as monotherapy for AML.  One important example is quizartinib (also known 
as AC220), a very potent and selective FLT3 inhibitor that was among the first to show efficacy 
as a single agent against FLT3-ITD+ AML (404, 475).  While quizartinib often induces rapid 
remission in FLT3-ITD+ AML, its use has been beset by acquired drug resistance, commonly in 
the form of FLT3 kinase domain mutations (404, 415, 476-478).  Unlike TL02-59, we found that 
quizartinib does not inhibit other AML-associated kinases including SYK, FES, HCK, or FGR in 
vitro; the same is true for other FLT3 inhibitors tested in the clinic, including sorafenib, 
sunitinib, and tandutinib (data not shown).  The activity of TL02-59 against virtually all known 
AML-related kinases within a relatively narrow overall specificity profile is a unique and 
important feature of TL02-59. In this way, TL02-59 may display the appropriately tuned 
‘polypharmacology’ (479) required for a kinase inhibitor drug with maximal efficacy against 
AML.  Finally, TL02-59 (or related compounds with similar specificity profiles) may induce 
sustained responses in vivo and exhibit a reduced propensity for acquired resistance due to 
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simultaneous inhibition of multiple AML kinase pathways.  Future work will address the 
molecular mechanisms of resistance for TL02-59 vs. quizartinib both in vitro and in vivo. 
2.4 MATERIALS AND METHODS 
2.4.1  Cell Culture, Reagents, and Antibodies 
The human AML cell lines MV4-11 (CRL-9591) and THP-1 (TIB-202) were obtained from the 
American Type Culture Collection (ATCC) and were cultured in RPMI 1640 medium, 
supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine (Life Technologies), 100 
units/ml of penicillin, 100 μg/ml of streptomycin sulfate, 0.25 μg/ml of amphotericin B 
(antibiotic-antimycotic, Life Technologies). Human 293T and Hs27 (CRL-1634) cells were 
obtained from the ATCC and cultured in Dulbecco's modified Eagle's medium (DMEM) 
containing 10% FBS and antibiotic-antimycotic.  
Tandutinib and staurosporine were obtained from LC Laboratories.  Sorafenib was 
purchased from ChemieTek and A-419259 was obtained from Sigma-Aldrich.  Custom synthesis 
of TL02-59 was performed by A Chemtek, Inc. (Worcester, MA).  
Primary antibodies used in this study were obtained from Santa Cruz Biotechnology 
(HCK, M-28; HcCK, N-30; pY99 anti-phosphoyrosine, SC-7020; FES, N-19) and Cell Signaling 
Technologies (FLT3, 3462S; SYK, 2712S). The activation loop antiphosphotyrosine antibody 
for Src-family kinases (pY418) used in this study was obtained from Invitrogen and the FES 
activation loop phosphospecific antibody (pY713) was previously developed by our group (480).  
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Alkaline phosphatase-linked secondary antibodies used in this study were purchased from 
Southern Biotech. 
2.4.2 Growth Inhibition and Apoptosis Assays 
Cells were seeded at a density of 100,000 cells per 1.0 ml in 48-well culture plates.  All 
compounds were made up as concentrated (1000x) stocks in DMSO and diluted 1/1000 when 
added to the cells.  Cell viability was assessed 72 hours later using the CellTiter-Blue Cell 
Viability assay (Promega) according to the manufacturer’s protocol.  Fluorescence intensity was 
measured using a SpectraMax M5 Multi-Mode Microplate Reader (Molecular Devices) with an 
excitation wavelength of 560 nM excitation and emission wavelength of 590 nm.  Apoptosis was 
assayed as caspase activation under the same cell culture conditions using the Apo-ONE 
Homogeneous Caspase-3/7 Assay (Promega) and the manufacturer’s protocol.  Fluorescence 
intensity was measured at an excitation wavelength of 485 nM and an emission wavelength of 
585 nM.  Where applicable, IC50 values were determined by non-linear regression analysis of 
concentration-response curves using the GraphPad PRISM software package (version 6.0). 
2.4.3 Immunoprecipitation and Western Blotting 
MV4-11 cells (2.5 x 106 cells in 5 mL) were cultured in the presence of kinase inhibitors or 
DMSO for 6 hours prior to lysis by sonication in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 
mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate) supplemented 
with 1 mM sodium orthovanadate, 1 mM sodium fluoride, 5 units/ml Benzonase (Novagen), and 
Protease Inhibitor Set III (Calbiochem).  Lysate protein concentrations were determined using 
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the Pierce Coomassie Plus assay reagent (Thermo Fisher).   FLT3, HCK, FES, and SYK were 
immunoprecipitated from 1 mg of cell lysate with 2 µg of antibody and 25 µL of protein G-
Sepharose beads (Invitrogen) overnight at 4 oC. Immunoprecipitates were collected by 
microcentrifugation and washed three times by resuspension in 1.0 ml of lysis buffer.  
Immunoprecipitated proteins were separated by SDS-PAGE, transferred to PVDF membranes 
and probed with the indicated antibodies followed by appropriate alkaline phosphatase-linked 
secondary antibodies. CDP-Star Western Blot Chemiluminescence Reagent (Perkin-Elmer) was 
used for detection. 
2.4.4 In vitro kinase assays  
Recombinant protein kinase assays were performed using the FRET-based Z’-LYTE Kinase 
Assay according to the manufacturer’s instructions (Thermo Fisher Scientific).  Recombinant 
FLT3-ITD, SYK, TAOK3, p38α, and FGR were purchased from Life Technologies, while 
recombinant FES (expressed in E. coli) and HCK (expressed in Sf9 insect cells) were purified as 
reported elsewhere (481, 482).  The Tyr-2 peptide substrate was used for FLT3-ITD, SYK, FES, 
HCK, and FGR while the Ser/Thr 7 peptide was used for TAOK3 and the Ser/Thr 4 peptide was 
used for p38α.  Kinase titration experiments were performed first to determine the kinase 
concentration required for approximately 90% phosphorylation of the peptide substrate with the 
ATP concentration set to the Km value for each kinase.  For inhibitor experiments, kinases were 
preincubated with inhibitors for 30 minutes, followed by addition of ATP and peptide substrate 
for 1 hour.  Reactions were quenched by addition of development reagent, followed by 
incubation for an additional hour prior to fluorescence measurements on a SprectraMax M5 
Multi-Mode Microplate Reader (Molecular Devices). Fluorophores were excited at a wavelength 
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of 400 nm; coumarin fluorescence and the fluorescein FRET signal were monitored at 445 nm 
and 520 nm respectively.  Data were then analyzed as the emission ratio of the coumarin to 
FRET signals; note that unphosphorylated peptide substrate remaining in the reaction is 
selectively cleaved by a protease present in the development reagent.  Data are then corrected for 
normalized control reactions run in the absence of ATP and normalized to the emission ratio 
obtained with a stoichiometrically phosphorylated control peptide.  IC50 values were calculated 
using the non-linear regression analysis of the resulting concentration response curves fit by the 
GraphPad PRISM software (version 6.0). 
2.4.5 RNA Isolation, cDNA preparation, qPCR  
Total RNA was isolated from cell lines and primary AML bone marrow samples using the 
RNeasy Plus Mini Kit (Qiagen) according to manufacturer’s instructions.  cDNA was then 
prepared from 1.0 µg of RNA using the RETROscript Reverse Transcription Kit (Ambion) 
according to the manufacturer’s instructions.  Each 20 μL RT reaction was then diluted 10-fold 
with water of reaction mix, and 8 µL was used for each real‐time quantitative PCR assay using 
SYBR Green detection (Qiagen) and gene‐specific QuantiTect primers (Qiagen).  The Ct values 
for each kinase was corrected for the corresponding GAPDH Ct value (ΔCt) and then converted 
to a relative expression value by calculating the base 2 antilog.  The relative expression value for 
each kinase within a given sample was then normalized to the average expression value for all 
TL02-59 target kinases examined within each sample to establish a relative kinase expression 
profile. 
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2.4.6  Lentivirus Production and shRNA Knockdown 
Human 293T cells were co-transfected with MISSION shRNA-containing lentiviral vectors 
(Sigma-Aldrich) and MISSION Lentiviral Packaging Mix using X-tremeGENE 9 DNA 
Transfection Reagent (Roche) according to the protocol provided with the lentiviral packaging 
mix.  A GFP lentiviral expression vector (Sigma-Aldrich) was used as a positive control for 
infection.  All lentiviral supernatants were titered using the HIV-1 p24 Gag AlphaLISA 
Detection Kit (Perkin-Elmer) according to the manufacturer’s instructions.  Equal amounts of 
each virus (250 ng p24 equivalents) were used to infect MV4-11 cells (2 x 105 in one mL of 
culture medium) in the presence of 8 µg/mL of polybrene in a 48-well plate.  Cells were 
centrifuged at 1350 x g for 4 hours to enhance infection efficiency and then incubated at 37 oC 
overnight.  The next day the medium was replaced and cell growth was measured daily using the 
CellTiter Blue Assay.  Three days after infection, the extent of kinase knockdown was 
determined by qPCR relative to cells infected with the GFP control virus.  Kinase Ct values were 
corrected for GAPDH expression and the effect of knockdown on kinase expression is expressed 
relative to values from cells infected with the control GFP virus as normalizer (ΔΔCt method). 
2.4.7 Culture of Primary AML Bone Marrow Samples 
Hs27 fibroblasts were mitotically inactivated by treating a confluent monolayer of cells in a 10 
cm tissue culture dish with 10 µg/mL of mitomycin C (MMC; Sigma) for 6 hours and 
cryopreserved until use.  De-identified primary human AML bone marrow samples were 
obtained from the Health Sciences Tissue Bank at the University of Pittsburgh as cryopreserved 
specimens.  Primary AML cells were cultured using the method of Klco, et al. (483) as follows:  
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MMC-treated Hs27 cells (5 x 105) were plated in each well of a 6-well plate and allowed to 
attach overnight.  Primary AML samples were thawed quickly, mixed with 10 mL of PBS, 
centrifuged at 1000 x g for 3 minutes and then resuspended in Iscove’s modified Dulbecco’s 
medium supplemented with 15% FBS, antibiotic-antimycotic, 2 mM L-glutamine, and human 
SCF (50 ng/mL), IL-3 (10 ng/mL), and IL-6 (20 ng/mL) (cytokines from Peprotech).  The 
primary AML bone marrow samples were then gently plated on the MMC-treated Hs27 
fibroblast feeder layers.  After one day in culture in a 6-well plate, the primary AML bone 
marrow samples were transferred to fresh feeder layers on 48-well plates.  Test compounds were 
then added and cultures were incubated for an additional 72 h prior to Cell Titer Blue assay as 
described above. 
The FLT3 genotype of each primary AML bone marrow sample was determined as 
follows. Genomic DNA (gDNA) was extracted from frozen bone marrow cells using the 
PureLink Genomic DNA Mini Kit (ThermoFisher) according to the manufacturer’s instructions.  
FLT3 exons 14-15, where ITD mutations common occur, were then amplified by PCR using the 
following primers: forward: 5’-GCAATTTAGGTATGAAAGCCAGC and reverse: 5’-
CTTTCAGCATTTTGACGGCAACC.  PCR reactions (15 µL) were run in DreamTaq Green 
Buffer (ThermoFisher) and contained 100 ng gDNA, 0.2 mM dNTPs, 1 μM of each primer, and 
1.25 U DreamTaq polymerase.  Denaturing, annealing, and extension steps were performed at 95 
oC for 30 s, 56 oC for 60 s, and 72 oC for 30 s, respectively, for 35 cycles.  Reactions also 
included an initial 9-minute denaturation step at 95 oC and a final 10-minute extension step at 72 
oC.  The resulting PCR products were run on 3% agarose gels to confirm the presence or absence 
of an ITD.  Samples containing ITDs were purified using the Gel DNA Recovery Kit (Zymogen) 
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and sequenced.  Genomic DNA was isolated from THP-1 cells (wild-type FLT3) and MV4-11 
cells (FLT3-ITD+), and included in negative and positive control reactions, respectively. 
2.4.8 Mouse AML Xenograft Model  
PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice were obtained from Jackson Laboratories and injected with 
human MV4-11 AML cells (107) suspended in PBS via the tail vein.  Control mice received a tail 
vein injection of PBS only.  All mice were left for 14 days to allow for AML cell engraftment to 
spleen and bone marrow.  After 14 days the mice received daily treatments of vehicle, 1 mg/kg 
TL02-59, 10 mg/kg TL02-59, or 10 mg/kg sorafenib for 21 days by oral gavage.  All compounds 
were suspended in 90% saline (Fisher), 5% solutol HS-15 and 5% N-methyl-2-pyrrolidone 
(Sigma), followed by vortexing and sonication to make 1 mg/mL stock solutions. TL02-59 fully 
dissolves in this combination of solvents while sorafenib remains as a suspension.  At the end of 
the study, all mice were sacrificed and blood, bone marrow and the spleen were collected.  
Histology was performed on sections of the spleen and trimmed femurs after decalcification in 
10% formic acid. 
2.4.9 Flow Cytometry 
Bone marrow, spleen, and blood samples from control and drug-treated mice were analyzed for 
the presence of human AML cells by flow cytometry following staining with human CD45-FITC 
(Clone HI30, BD Biosciences), mouse CD45-PE (Clone 30-F11, BD Biosciences), and human 
CD33-APC (Clone WM53, BD Biosciences) antibodies according to the manufacturer’s 
instructions.  Red blood cells present in the bone marrow and spleen were lysed in 10 mM 
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KHCO3, pH 7.4, 155 mM NH4Cl, and 130 µM EDTA prior to antibody staining in FACS buffer 
(PBS, pH 7.5, 3% FBS, 0.02% NaN3, 1 mM EDTA).  Twenty-five μL of blood from each animal 
was also stained with the three antibodies and then fixed and lysed using a fix/lyse solution (BD 
Biosciences).  Cells were then analyzed on a BD Accuri C6 Flow cytometer and resulting data 
were evaluated using FlowJo software. 
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3.0  OVERALL DISCUSSION 
3.1 SUMMARY OF FINDINGS AND SIGNIFICANCE 
Despite unprecedented knowledge of the cytogenetic abnormalities and genetic mutations that 
drive AML, the overall survival rate is only twenty-five percent, with elderly patients faring 
worse than younger patients.  Furthermore, standard therapy for all AML patients, with the 
exception of APL patients, is still high dose cytotoxic chemotherapy which most elderly patients 
are ineligible to receive.  The standard chemotherapy treatment used today was originally 
described in 1973 and has undergone only minor changes since that time.  Relapse rates in the 
first three years of diagnosis are around fifty percent and for most patients, hematopoietic stem 
cell transplant offers the only hope of a cure.   
AML has one of the lowest median mutation rates of all human cancers and a significant 
number of recurrent mutations have been identified through genome-wide sequencing studies.  
To date, the most commonly mutated protein in AML is the FLT3 receptor tyrosine kinase which 
is mutated in approximately thirty percent of AML cases.  In about twenty-five percent of 
patients, FLT3 is mutated through an ITD, which produces a constitutively active kinase that 
activates a number of signaling pathways involved in cell survival and proliferation.  The 
activation of many of these pathways is co-dependent on a small number of essential cytoplasmic 
tyrosine kinases, including HCK, FGR, LYN, SYK and FES.   
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The development of clinically active FLT3 inhibitors is of major interest for the treatment 
of AML cases with activating mutations in this receptor tyrosine kinase.  However, FLT3 
inhibitors tested in clinical trials thus far have had limited success, especially as single agents.  
The first-generation inhibitors were designed to target a number of receptor tyrosine kinases and 
not FLT3 specifically, resulting in lower binding affinities and toxicities due to off-target effects.  
Second-generation inhibitors have had significantly more success as single agents due to 
improved affinity and specificity for FLT3.  However, this specificity left these inhibitors 
vulnerable to the development of resistance, most commonly through inhibitor resistance 
mutations in the tyrosine kinase domain.  
Since the identification of the clinical utility of imatinib, most drug discovery has focused 
on a single drug targeting a single kinase.  This selectivity is supposed to limit off-target 
toxicities due to inhibition of multiple kinases.  However, these inhibitors are often subject to the 
development of resistance, particularly in cancer treatment (484).  Furthermore, due to targeting 
a single kinase, upregulation of collateral signaling pathways occurs as an alternative mechanism 
of resistance.  The combination of highly selective inhibitors has emerged as a possible 
mechanism to reduce resistance and increase potency.  However, combination of toxicities, 
interactions between compounds, and the difficulties in finding proper dosing regimen are all 
potential pitfalls of using combination therapies (485).  To bypass these pitfalls, the concept of 
polypharmacology has recently emerged in drug discovery.  In this case, a single inhibitor is 
purposefully designed to target a small set of kinases.  This eliminates the need for combination 
therapies, reduces the rate of resistance, increases potency, and some studies have indicated that 
activity at multiple therapeutic targets can reduce toxicities (486).  Notably, many kinase 
inhibitors on the market inhibitor multiple targets, and in some cases these ‘off-target’ effects are 
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critical to their efficacy.  However, the main difficulty with polypharmacology is identifying the 
proper combination of targets to increase efficacy and reduce toxicities.    
Due to the lack of efficacy and the quick development of resistance of the clinical FLT3 
inhibitors, we decided to take a ‘polypharmacological’ approach to treating FLT3-ITD+ AML by 
targeting FLT3 and its best defined downstream kinase partners; HCK, SYK and FES.  In the 
first Aim of my thesis we screened a small library of compounds and identified TL02-59, a 
kinase inhibitor with efficacy against FLT3, HCK, SYK, and FES.  The potency of TL02-59 led 
us to wonder which targets are most critical for efficacy and whether any novel targets could be 
discovered. Therefore, in the second Aim of my thesis we performed kinome-wide profiling of 
TL02-59 and explored expression of the target kinases in primary AML bone marrow samples.   
3.1.1 Polypharmacology screening approach yields a highly active AML-associated 
tyrosine kinase inhibitor, TL02-59 
To test our polypharmacology hypothesis, we screened a small library of N-phenylbenzamide 
compounds and identified TL02-59, a compound with three-digit nanomolar activity against 
FLT3, HCK, SYK and FES in vitro.  To further explore the efficacy of this compound in cells, 
we tested it against and THP-1 and MV4-11 cells.  TL02-59 was effective in the picomolar range 
against MV4-11 cells but had no effect on THP-1 cells.  The fact that the cell line potency is 
lower than the in vitro kinase potency suggests that the cellular potency results from the 
combination of targeting all four kinases.  Notably, all four kinases are expressed and active in 
MV4-11 cells, and treatment with TL02-59 at just 100 nM inhibits all four kinases.  Furthermore, 
the lack of potency against THP-1 cells suggests that a kinase fingerprint of therapeutic response 
 98 
exists with this compound and that, at least in cell lines, the potency we observed in MV4-11 
cells was not due to toxicity.   
To validate TL02-59 in a more AML-relevant context we tested the potency of the 
compound against a panel of 26 primary AML bone marrow samples: 13 with FLT3-ITD 
mutations and 13 with wild-type FLT3.  We discovered a range of potencies for growth 
inhibition of these samples, from 77 nM to greater than 3 μM.  The range of potencies did not 
surprise us as the samples varied in cytogenetic abnormalities, chromosomal changes, age and 
genetic alterations.  However, the one surprise from this experiment was that the four most 
sensitive samples were FLT3-WT.  I will describe in section 3.1.2 one potential explanation for 
why these samples were so sensitive, but it suggests that TL02-59 could be applicable to other 
subsets of patients, not just FLT3-ITD+ patients. Further genomic sequencing of these samples to 
determine concurrent genetic mutations could allow us to further define the subgroup of patients 
that would respond.   
Finally, we tested TL02-59 efficacy in vivo using a mouse xenograft model of AML.  
Oral TL02-59 at 10 mg/kg once per day for just three weeks completely eliminated xenografted 
human MV4-11 AML cells from the peripheral blood and spleen.  Additionally, we observed a 
sixty percent reduction in bone marrow involvement after only three weeks of treatment.  These 
data demonstrate that TL02-59 is orally bioavailable and efficacious in this mouse model.  
Furthermore, TL02-59 is capable of substantially reducing bone marrow engraftment as a single 
agent.  Future experiments will address whether higher doses or a longer treatment schedule will 
result in complete eradication of the engrafted AML cells.  We also need to follow the survival 
of the mice following cessation of drug treatment, and look for leukemia relapse of drug-resistant 
cells.  Notably, a subset of the mice exhibited potential toxicity to TL02-59, as displayed by 
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weight loss.  However, in most cases cutting the dose in half for a day or two allowed the mice to 
regain weight and then continue on the normal dosing schedule.  We delivered TL02-59 once 
daily by oral gavage so one possibility to eliminate this weight loss issue is to determine a dosing 
schedule that allows the mice a couple of off days.  This would likely reduce toxicity associated 
with daily dosing.  Even though we noticed some weight related toxicity, upon gross 
examination neither the liver nor the kidneys displayed any abnormalities, suggesting that weight 
loss was not an effect of toxicity to either of those organs.  
In summary, taking a polypharmacological approach we identified a highly active 
compound with efficacy in vitro, in cell lines, in primary AML bone marrow samples, and in an 
in vivo model of AML.  While many dual FLT3 kinase inhibitors are under development, this is 
the first kinase inhibitor to our knowledge designed specifically to target FLT3 and three linked 
tyrosine kinases; HCK, SYK and FES.  This inhibitor displays greater activity in cells than in 
targeting either of the kinases in isolation, suggesting that the potency comes from inhibiting the 
combination of kinases.  A kinase inhibitor targeting multiple AML-associated kinases holds the 
potential to significantly reduce the rate of acquired resistance as it would be necessary for 
multiple kinases to develop inhibitor resistance mutations.  Furthermore, since a multitude of 
signaling pathways are presumably inhibited by this compound, the ability for AML to 
upregulate collateral pathways will be diminished.  As mentioned earlier, one mechanism of 
resistance to FLT3 inhibitor is upregulation of collateral signaling pathways, particularly the 
PI3K/AKT and the MEK/ERK pathways.  Furthermore, upregulation of anti-apoptotic proteins is 
also seen.  Knockdown of FES and LYN inhibits some PI3K pathway members, FES knockdown 
reduces BCL-xL expression and SYK is implicated in the activation of ERK downstream of 
FLT3. Assuming that each of these tyrosine kinases helps to activate bypass pathways in FLT3 
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resistant cells, inhibition with TL02-59 could reduce this mechanism of resistance.  Finally, the 
odds of each kinase being expressed and active in cells other than AML blasts is low, thus TL02-
59 holds the potential to significantly limit treatment related toxicity. 
3.1.2 Expression and identification of TL02-59 target kinases in AML 
The potency of TL02-59 against MV4-11 cells pushed us to investigate the full range of TL02-
59 target kinases.  We hypothesized that inhibition of other kinases beyond FLT3, HCK, SYK 
and FES were contributing to TL02-59 efficacy. To begin to explore other targets, we performed 
a KINOMEscan assay and discovered that TL02-59 was remarkably selective, targeting only 23 
kinases out of the 456 screened.  Included in those twenty-seven kinases were all four of the 
AML-associated kinases we used to identify TL02-59.  After obtaining 26 primary AML bone 
marrow samples, we performed quantitative real-time RNA expression analysis for each of the 
27 TL02-59 target kinases.  As mentioned in section 3.1.1, half of the primary AML bone 
marrow samples were FLT3-WT and the other half were FLT3-ITD+.  Surprisingly, the 
expression pattern of all 27 kinases was almost identical between the FLT3-WT samples and 
FLT3-ITD samples.  In each case the same 15 kinases were constitutively expressed.  This 
suggests that although these AML samples are driven by different mechanisms, a shared set of 
kinases contributes to oncogenesis.  Using IC50 values from the TL02-59 growth inhibition 
curves described in section 3.1.1 we correlated expression of each kinase with response across all 
26 samples.  We discovered that relative expression of HCK, FGR, LYN and SYK positively 
correlated with TL02-59 response. Interestingly, each of the four AML samples that were most 
sensitive to TL02-59 expressed high levels these four kinases, and were wild-type for FLT3.  
Notably, they also expressed high levels of FLT3, even though it did not correlate with response.  
 101 
These data suggest that response to TL02-59 is determined by expression of a set of kinases and 
not expression of one particular kinase, validating the polypharmacology approach to tyrosine 
kinase inhibition in AML.  Furthermore, since the expression of each kinase is important for 
efficacy, predicting response to TL02-59 would involve a model that incorporates the expression 
of each of these kinases.  Finally, I will note that one Src-family kinase, YES, showed a negative 
correlation with TL02-59 response even though it was not very highly expressed in any of the 
samples.  This suggests that YES may actually play an opposing role to the other SFKs in AML 
blasts, raising the possibility that inhibition of some kinases may be detrimental to efficacy.  For 
example, YES may contribute to growth suppression, to balance the growth and survival signals 
of other kinases, or fulfill a role in differentiation.  Support for this idea comes from previous 
work in our group, where SRC and YES were shown to have opposing roles in embryonic stem 
cell growth and differentiation, despite their close phylogenic relationship (487, 488).   
Given that three members of the Src kinase family, HCK, LYN and FGR, are correlated 
with response to TL02-59 we wanted to determine if inhibition of SFK activity alone accounted 
for the potency of TL02-59.  To investigate this hypothesis, we tested A-419259, a well-known 
pyrrolopyrimidine pan-SFK inhibitor, against MV4-11 cell proliferation and determined an IC50 
value of 37 nM.  That potency is approximately thirty-fold lower than what we observed for 
TL02-59 in this cell line, suggesting that TL02-59 inhibits targets beyond the SFKs that are 
critical to potency.  To identify other kinases that may represent TL02-59 targets in AML, we 
performed KINOMEscan analysis on A-419259 and discovered it was even more selective than 
TL02-59, targeting just 19 kinases out of 468 tested.  Upon comparing KINOMEscan profiles, 
we identified four kinases, SYK, p38α, TAOK3 and STK10, which were inhibited by TL02-59 
but not A-419259 and constitutively expressed in primary AML bone marrow cells.  While SYK 
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and p38α have defined roles in AML pathogenesis, neither TAOK3 nor STK10 has been 
examined in the context of AML.  To investigate their role in MV4-11 cell growth, we 
performed shRNA knockdown of both kinases in MV4-11 cells.  While knocking down STK10 
had no effect on MV4-11 cells, knockdown of TAOK3 completely inhibited cell growth.  These 
data suggest that inhibition of some Ser/Thr kinases, not just tyrosine kinases, contributes to 
TL02-59 potency.  Among the few studies that have investigated TAOK3, two functions have 
been discovered: inhibition of JNK and activation of p38α in response to genotoxic stresses.  
JNK signaling is known to be pro-apoptotic, so inhibiting TAOK3 could increase apoptotic 
signaling by relieving JNK inhibition in AML cells.  Furthermore, p38α signaling in response to 
genotoxic stresses is known to induce pro-survival signaling which is blocked directly by TL02-
59.  In either case, inhibition of TAOK3 could reduce anti-apoptotic signaling, pushing the cells 
toward apoptosis.  This raises the intriguing possibility that TL02-59 could synergize with 
existing chemotherapy agents used in AML to induce apoptosis.  As it becomes increasingly 
clear that combination therapy is more likely to be efficacious in AML, combining multitargeted 
kinase inhibitors with existing chemotherapy drugs is likely to be advantageous (388, 397, 399).  
A related advantage is the potential for the addition of a potent multi-targeted compound to 
reduce the necessary chemotherapy dose.  This would reduce toxicities related to treatment.   
In summary, we explored the full range of kinase targets for TL02-59 in AML and 
discovered that expression HCK, LYN, FGR and SYK were critical for efficacy.  Furthermore, 
comparative KINOMEscan analysis with A-419259 suggested that FES as well as the Ser/Thr 
kinases p38α and TAOK3 are also important targets for TL02-59.  Our discovery that the 
expression of these TL02-59 target kinases is remarkably consistent across a broad array of AML 
genotypes suggests that TL02-59 could be therapeutic for a broad spectrum of AML patients.  
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Furthermore, HCK was recently identified as overexpressed in LSCs versus HSCs suggesting it 
is a potential target for LSC therapy.  Additionally, one study also identified LYN as being 
expressed and active in the LSC compartment.  Since TL02-59 efficacy correlates most closely 
with HCK and LYN expression, it is possible that TL02-59 is capable of eliminating LSCs, the 
main cause of relapse in AML patients.  Finally, given the role of TAOK3 in genotoxic stress 
signaling and apoptosis, TL02-59 seems likely to synergize with existing chemotherapeutic 
agents used in AML treatment.        
3.2 FUTURE DIRECTIONS 
3.2.1  Determine efficacy of TL02-59 in FLT3 inhibitor-resistant cells 
Clinical trials of FLT3 inhibitors have largely produced underwhelming results.  Despite high 
hopes, single agent therapy has produced low response rates and quick relapse rates.  Quizartinib 
is the most efficacious FLT3 inhibitor to date, with a 53% response rate as a single agent, but 
responses are limited in duration from a few weeks to a few months due to the development of 
resistance.  The main cause of resistance is tyrosine kinase domain mutations that inhibit 
quizartinib binding.  Most commonly these mutations occur as D835Y, Y842C or F691L 
mutations.  Midostaurin is a staurosporine derivative that again produces only transient clinical 
responses.  Inhibitor resistance mutations to midostaurin occur most commonly as N676D, 
F691I, and G697R mutations.  
One potential advantage of the polypharmacology of TL02-59 is that it is not dependent 
on one single kinase for its potency. While we provided evidence to suggest the dependency of 
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TL02-59 on multiple kinases, we never directly assessed the potency of TL02-59 in the presence 
of inhibitor resistance mutations.  As mentioned above, FLT3 inhibitor resistance mutations pose 
a significant clinical challenge so I propose that future studies investigate the efficacy of TL02-
59 against cells expressing inhibitor resistance mutations.  One caveat to these experiments is 
that the cell line we choose must express HCK, FGR, LYN, SYK, and FES; otherwise we will 
simply be assessing the ability of TL02-59 to inhibit FLT3 inhibitor resistance mutations and not 
addressing the combination of kinases.  The one cell line that meets these criteria is MV4-11 
cells.  Using CRISPR/Cas9 it would be possible to make each of the FLT3 inhibitor resistant 
mutations mentioned above. I hypothesize that TL02-59 would lose some potency as inhibition 
of each kinase is important for its overall effect.  However, TL02-59 should still be a potent 
inhibitor since it could inhibit all of its other targets.  Subsequent experiments could investigate 
the role of inhibitor resistant mutations in each of the other AML-associated kinases, HCK, FGR, 
LYN, SYK, and FES. Again, I hypothesize that in each case the TL02-59 would lose some 
potency but still effectively inhibit MV4-11 cells since it can still inhibit its other known targets.  
While FLT3 inhibitor resistant mutations would be focused on those that are clinically identified, 
no clinically relevant inhibitor resistant mutations have been identified in the FLT3-associated 
kinases.  To identify potential inhibitor resistant mutations, we could model TL02-59 binding 
into the kinase domains of each of the kinases and determine critical residues for binding.  These 
residues would then have to be tested empirically through the purification and subsequent in 
vitro testing of kinase domains containing the inhibitor resistant mutations.          
A complimentary unbiased approach for identifying the rate of resistance and resistance 
mechanisms to TL02-59 would be to grow MV4-11 cells in the presence of sub-lethal doses of 
TL02-59.  The dosage could continually be increased by small increments selecting for the 
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inhibitor resistant clones.  At the conclusion of this experiment, RNAseq could be performed on 
the resistant clones to identify resistance mechanisms, whether it is upregulation of a distinctive 
pathway or acquisitions of inhibitor resistant mutations.  This experiment would also determine 
the rate of resistance against TL02-59.  I hypothesize that if done alongside quizartinib, TL02-59 
would display a reduced rate of resistance compared to quizartinib, due to the multi-targeted 
nature of the compound.  Furthermore, while quizartinib resistance would appear in the form of 
FLT3 inhibitor resistant mutations, the mechanism(s) for TL02-59 resistance would be more 
diverse as the compound is not dependent on one target for efficacy.       
3.2.2 Determine potency of TL02-59 against LSCs in vitro and in vivo 
Elimination of LSCs remains a clinical challenge to AML therapy, as LSCs are the main cause of 
relapse in patients.  Elimination of LSCs would significantly reduce relapse rates of AML, which 
are approximately 50-70%.  Furthermore, LSCs are one of the reasons bone marrow transplants 
fail, suggesting that elimination of LSCs could increase the effectiveness of bone marrow 
transplants.  Recently, HCK was identified as differentially expressed in LSCs versus HSCs, 
suggesting it may provide a viable target for anti-LSC therapy.  A known inhibitor of HCK, A-
419259, reduced the LSC population in a bone marrow transplant model of AML.  Furthermore, 
LYN was also identified as expressed and active in the LSC compartment.  In this thesis I 
identified TL02-59 as a more potent inhibitor than A-412959 yet it maintains potent activity 
against HCK and all other myeloid Src-family kinases.  If TL02-59 is capable of eliminating 
LSCs, it could not only treat AML but also significantly reduce relapse rates. 
LSCs are often defined by their cell surface markers and most commonly associated with 
the Lin-CD34+CD38- population.  To begin testing the efficacy of TL02-59 against LSCs, Lin-
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CD34+CD38- cells could be sorted out of primary AML patient samples, and cultured in vitro 
using established methods.  Simple experiments determining LSC survival in the presence of 
TL02-59 could then be performed as a critical first step.  It would also be very interesting to 
repeat TL02-59 target kinase expression profiling on LSCs derived from patient bone marrow, to 
determine if they are similar to those already reported here for unfractionated bone marrow 
specimens.  While LSC assays would provide proof-of-concept for TL02-59 action in vitro, the 
ultimate determination of LSC elimination would need to occur in patient derived xenograft 
(PDX) models of AML.  PDX models require the xenotransplantation of primary AML samples 
into immunocompromised mice; which proliferate and recapitulate the malignancy observed in 
the AML source.  PDX models of AML would be treated with TL02-59 for a specified period of 
time.  Then the same number of viable hCD45+ bone marrow cells from the primary recipient 
would be transplanted into a naïve secondary recipient mouse.  The ability of the transplanted 
cells to engraft the secondary recipient would determine if LSCs are eliminated by TL02-59 
treatment.     
HCK and LYN are both critical targets of TL02-59 and are expressed and active in LSCs, 
suggesting that TL02-59 has the potential to eliminate LSCs.  Elimination of LSCs would 
significantly reduce the rate of relapse in patients and improve clinical outcomes.  If TL02-59 is 
capable of eliminating LSCs it would provide a very strong rationale for further clinical 
development of this compound.   
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3.3  CONCLUDING REMARKS 
Significant breakthroughs in our understanding of AML have occurred over the last 40 years.  
However, only limited changes have been made to standard of care treatment for AML and these 
changes have resulted in only minimal outcome improvement. Outcomes for AML remain 
dismal compared to other types of leukemia which have made significant strides in treatment 
response rates. The overall survival rate for AML is approximately 25%.  Many targeted 
treatment options are currently undergoing evaluation in clinical trials, including FLT3 
inhibitors.  It was initially hoped that FLT3 inhibitors would revolutionize treatment of AML the 
same way that imatinib revolutionized CML treatment.  However, first-generation FLT3 
inhibitors have not produced durable clinical responses in patients and have been beset with 
toxicity issues. Second-generation FLT3 inhibitors have significantly improved clinical 
responses, with approximately half of patients achieving a clinical response.  However, the 
duration of response is limited by the development of resistance.  Furthermore, LSCs still remain 
a significant challenge to any AML therapy and ultimately are the cause of relapse in patients. 
Treatment of FLT3 still holds major promise for therapy in AML; however, resistance must be 
reduced or eliminated.  In this context, we set out to identify a potent inhibitor of FLT3-ITD+ 
AML that is not solely dependent on FLT3 inhibition for its activity.  We identified TL02-59, a 
potent inhibitor of FLT3-ITD+ cell growth in vitro and in vivo.  The mechanism of action for 
TL02-59 appears to be driven not only through FLT3-ITD inhibition but also through inhibition 
of the SFKs, SYK, FES, and some Ser/Thr kinases.  Given that potency depends on the 
inhibition of multiple kinases, TL02-59 holds the potential to reduce the rate of resistance. 
Furthermore, TL02-59 might also inhibit cells resistant to current FLT3 inhibitors which only 
depend on FLT3 inhibition.  Notably, we identified few differences in the expression of TL02-59 
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target kinases in FLT3-WT versus FLT3-ITD bone marrow samples, including samples with 
very complex cytogenetic profiles, suggesting that TL02-59 will potentially be clinically active 
beyond the FLT3-ITD+ subset of patients.  Finally, two targets of TL02-59 have been identified 
as critical for LSCs survival in other work (HCK and LYN), suggesting that TL02-59 could 
eliminate LSCs as well as bulk AML blasts.  The data described in this study and the potential 
for reduced resistance and LSC therapy support further clinical development of TL02-59 for the 
treatment of AML.    
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APPENDIX A 
DUAL INHIBITION OF FES AND FLT3 TYROSINE KINASE ACTIVITIES 
POTENTLY BLOCKS AML CELL PROLIFERATION 
A.1 INTRODUCTION 
Acute myelogenous leukemia (AML) is the most common hematologic malignancy in adults 
(207).  The usual standard of care for AML is cytotoxic chemotherapy that has changed little in 
the last 40 years, leading to a stagnant overall survival rate of approximately 25% (232, 448).  
While numerous cytogenetic abnormalities and mutations have been identified in AML, the 
receptor tyrosine kinase FMS-like tyrosine kinase 3 (FLT3) is mutated in approximately 30% of 
all AML cases (8, 422).  FLT3 mutations occur as internal tandem duplications (ITDs), in-frame 
duplications of varying length within the juxtamembrane region, or as tyrosine kinase domain 
(TKD) point mutations, most commonly at position D835 within the activation loop of the kinase 
(231, 421). Both types of mutations result in a constitutively active kinase that drives AML 
pathogenesis. FLT3-ITD mutations in particular are associated with a poor prognosis relative to 
other forms of AML (385, 450).  
The FES tyrosine kinase belongs to a unique family of tyrosine kinases and is highly 
expressed in hematopoietic cells, particularly in the myeloid lineage (378, 383). Originally 
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identified as the cellular homolog of the transforming oncogene present in several avian and 
feline sarcoma viruses, FES kinase activity is tightly regulated in cells (489). FES normally 
functions as a signaling mediator downstream of growth factor, cytokine and immune cell 
receptors and is involved in hematopoietic cell growth, survival and differentiation as well as 
innate immune responses (490).                       
Voisset and colleagues have implicated FES as an important downstream signaling 
partner for FLT3-ITD+ AML (384).  They discovered that FES was constitutively active in two 
FLT3-ITD+ AML cell lines, MV4-11 and MOLM-14, as well as in primary AML bone marrow 
samples.  Knockdown of FLT3 in both cell lines significantly reduced FES kinase activity and 
decreased FLT3-ITD+ AML cell growth to a similar extent as knockdown of FLT3-ITD itself.  
Furthermore, the activity of many of the oncogenic signaling mediators for FLT3-ITD, 
particularly STAT5 and PI3K, were also substantially decreased in FES-knockdown AML cells.  
Finally, treatment of primary AML patient samples with the FLT3 inhibitor, SU5416, reduced 
both FLT3 and FES activation. These data strongly suggest that FES is essential for the 
activation of signaling pathways downstream of FLT3-ITD, and that inhibition of FES kinase 
activity may be therapeutically beneficial in AML.  In the present study, we explored the role of 
FES kinase activity in AML cell growth using a panel of ATP-site inhibitors selective for FES, 
selective for FLT3, or with dual activity for FES and FLT3.  Our results show that inhibition of 
FES kinase activity alone is sufficient to block AML cell growth, and that inhibitors with dual 
activity against both FLT3-ITD and FES are even more active, with IC50 values in the low nM 
range. 
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A.2 RESULTS 
To test the hypothesis that inhibition of FES kinase activity may be of therapeutic relevance to 
AML, we first investigated the effects of FES kinase inhibitors from three distinct chemical 
classes (Figure 14A) previously identified by our lab (481) on the growth of AML cell lines 
either wild-type for FLT3 (THP-1) or with an ITD (MV4-11). All of the FES kinase inhibitors 
tested blocked the growth of the MV4-11 cells in a concentration-dependent manner, while 
having minimal effects on the growth of THP-1 cells (Figure 14B).  However, inhibitors from 
the diaminopyrimidine (TAE-684) and pyrrolopyridine (HG7-92-01) classes were significantly 
more potent, with IC50 values of 90 and 36 nM, respectively, than the two pyrazolopyrimidines 
(WZ4-49-1 and WZ4-49-8), which yielded IC50 values in the single-digit micromolar range. 
Notably, both TAE-684 and HG7-92-01 were significantly more potent than the FLT3-selective 
inhibitor, tandutinib, in MV4-11 cells. 
Next, we investigated whether FES inhibitors were able to induce programmed cell death 
in FLT3-ITD+ AML cells. MV4-11 and THP-1 cells were treated with each inhibitor at a 
concentration of 1.0 µM, and induction of apoptosis was assayed as Caspase 3/7 activity three 
days later. All four compounds induced significant apoptosis under these conditions in MV4-11 
cells but not in THP-1 cells, which is consistent with the observation that FES is constitutively 
active solely in MV4-11 cells (384) (Figure 14C). However, both TAE-684 and HG7-92-01 
induced significantly more apoptosis under these conditions than the two pyrazolopyrimidines. 
Data presented so far show that all four FES inhibitors were able to induce growth arrest 
and apoptosis in FLT3-ITD+ AML cells. However, the differences in potency across the 
compounds suggested that inhibition of other kinase targets, including FLT3-ITD itself, may be 
account for the higher potency of the diaminopyrimidine and pyrrolopyridine inhibitors.   
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Figure 14: FES tyrosine kinase inhibitors induce growth arrest and apoptosis in the FLT3-ITD+ 
AML cell line, MV4-11. 
A) Chemical structures of the tyrosine kinase inhibitors used in this study. B) Dose-response curves of MV4-11 and 
THP-1 AML cells treated with varying doses of the inhibitors for 72 hours. Cell viability was measured using the 
Cell Titer Blue Assay (Promega).  C) Apoptosis was measured after 72 hours of treatment with each of the inhibitors 
at 1 μM using the Apo-ONE Caspase 3/7 Assay (Promega). All experiments were performed in triplicate.  Asterisks 
indicate statistical significance with p < 0.05. 
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Previous KINOMEscan analysis of the kinome-wide target specificity profiles of these four 
compounds support this idea (491). KINOMEscan data show that the more potent compounds, 
TAE-684 and HG7-92-01, bind to a wider range of kinases (including FLT3) compared with the 
two less potent pyrazolopyrimidines, which are more selective for FES and do not bind to FLT3.  
To compare the inhibitory profiles of each compound for FES and FLT3 directly, we performed 
in vitro kinase assays using recombinant purified full-length FES and FLT3 kinase domains 
(wild-type, and the AML-associated mutants, FLT3-ITD and FLT3-D835Y).  As shown in Table 
8, the most potent inhibitors of MV4-11 cell growth and survival inhibited both FES and FLT3 
with similar potencies.  For example, the pyrrolopyridine analog, HG7-92-01, inhibited both FES 
and wild-type FLT3 in the 500 nM range, and also potently inhibited MV4-11 cell growth (IC50 
of 36 nM). This compound is also a potent inhibitor of the FLT3-ITD kinase domains, with an 
IC50 value of 149 nM. A very similar inhibitory profile was also observed for TAE-684 with 
FES, wild-type FLT3, and FLT3-ITD.  In contrast, the pyrazolopyrimidine analog, WZ4-49-8, 
inhibited both forms of FES in the 700 nM range, but was much weaker against the wild-type 
and ITD forms of FLT3 (about 20-fold lower potency). This difference may explain the lower 
potency of WZ4-49-8 for inhibition of MV4-11 cell growth (IC50 value of 2.1 μM). The closely 
related pyrazolopyrimidine analog, WZ4-49-1, showed a similar inhibitory profile as WZ4-49-8, 
although the difference in potency between full-length FES and FLT3-ITD was only about 3-
fold.  This compound produced an IC50 value for MV4-11 growth inhibition of about 800 nM, 
suggesting that it may target not only FES but also FLT3 to some extent. 
We next investigated whether transformation with FLT3-ITD is directly responsible for 
activation of FES in a myeloid cell background. For these studies, we used the human myeloid 
leukemia cell line TF-1, which expresses endogenous FES proteins but not FLT3.  These cells 
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are dependent on GM-CSF for growth and survival, and have been previously shown to undergo 
transformation to a cytokine-independent phenotype following introduction of another 
transforming oncogene BCR-ABL (492). To determine if TF-1 cells were also susceptible to 
transformation by active mutants of FLT3 associated with AML, we transduced TF-1 cells with 
retroviral vectors for wild-type FLT3, a FLT3-ITD mutant identical to the one found in MV4-11 
cells, and an active FLT3 point mutant, D835Y. As shown in Figure 15A, TF-1 cells transduced 
with the ITD and D835Y mutants of FLT3 underwent transformation to cytokine independent 
 
Inhibitors 
MV4-11 Cells  
(IC50, nM) 
In vitro Kinase Assay (IC50, nM) 
Compound Class FES FLT3-WT FLT3-ITD 
FLT3-
D835Y 
TAE-684 Diaminopyrimidine 90 569 536 120 218 
HG7-92-01 Pyrrolopyridine 36 527 536 149 3,646 
WZ4-49-1 Pyrazolopyrimidine 760 494 3,138 1,390 642 
WZ4-49-8 Pyrazolopyrimidine 2153 706 13,997 14,345 2,347 
Tandutinib Piperazinylquinazoline 244 >100,000 580 788 7,370 
 
Table 8:  In vitro inhibitor specificity profiles with recombinant FES and FLT3 kinase domains.  
In vitro kinase assays were performed with recombinant full-length FES as well as wild-type (WT), ITD and D835Y 
forms of the FLT3 kinase domain (Z’-Lyte assay; Life Technologies). Each inhibitor was tested in triplicate over a 
range of concentrations with the ATP concentration set to the Km value for each kinase.  IC50 values were calculated 
by non-linear regression analysis of each of the dose-response curves. Also included in the table are the IC50 values 
for inhibition of MV4-11 AML cell growth, calculated from the dose-response curves shown in Figure 1. In vitro 
kinase data were produced by Dr. Sabine Hellwig, a former postdoctoral fellow in our group. 
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growth, while cells expressing wild-type FLT3 did not. 
We next explored the expression and activity of both FLT3 and FES kinases in control 
and FLT3-transformed TF-1 cell populations. For these experiments, we immunoprecipitated 
each kinase protein, and then assessed activity by immunoblotting FES with antibodies for the 
activation loop phosphotyrosine (pTyr713) and FLT3 with general antiphosphotyrosine 
antibodies.  As shown in Figure 15B, FLT3 kinase protein was readily detected in the three TF-1 
cell populations transduced with FLT3 retroviruses, but was absent in the parental TF-1 cells as 
expected. However, only the ITD and D835Y forms of FLT3 showed reactivity with the 
antiphosphotyrosine antibody, indicating that they are constitutively active.  These findings are 
consistent with the GM-CSF-independent outgrowth of these two cell populations.  Endogenous 
FES kinase protein was also readily detected in all four cell populations. Interestingly, 
endogenous FES was active only in TF-1 cells transformed with FLT3-ITD, and not in the FLT3-
D835Y cells or either of the control cell populations.  This observation suggests important 
structural differences between these two active forms of FLT3 in terms of downstream effector 
kinase coupling (see Discussion). 
We next investigated whether transformation of TF-1 cells with active forms of FLT3 
resulted in sensitization to growth suppression by the panel FES inhibitors. Results obtained with 
TF-1 cells expressing FLT3-ITD recapitulated the effects seen in the FLT3-ITD+ AML cell line, 
MV4-11.  As shown in Figure 16, TAE-684 and HG7-92-01 treatment resulted in potent 
inhibition of TF-1/FLT3-ITD cell growth, with IC50 values of 160 and 59 nM, respectively. The 
pyrazolopyrimidine FES inhibitors, WZ4-49-1 and WZ4-49-8, which showed lower activity 
against FLT3-ITD than FES in vitro, inhibited TF-1/FLT3-ITD cell growth with IC50 values of  
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Figure 15: Active mutants of FLT3 (FLT3-ITD and FLT3-D835Y) transform human TF-1 cells to 
cytokine independent growth. 
A) The human myeloid TF-1 cells were transduced with recombinant retroviruses carrying wild-type (WT), ITD, or 
D835Y forms of FLT3. Each of the TF-1 cell populations, along with parental TF-1 cells, were cultured in the 
absence of GM-CSF, and viable cell outgrowth was monitored by Cell Titer Blue assay (Promega) over the course 
of 96 hours. The mean fluorescence values from triplicate cultures are shown.  B) FES and FLT3 kinase proteins 
were immunoprecipitated from each of the cell populations shown in A, followed by immunoblotting with 
antibodies to phosphotyrosine (pTyr), the FES activation loop phosphotyrosine (pFES), as well as the FLT3 and 
FES proteins. This experiment was performed in triplicate with comparable results, and a representative example is 
shown. 
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cells expressing wild-type FLT3 or the parental cell line. Comparison of the inhibitor selectivity 
profiles against the FES and FLT3-ITD kinases in vitro (Table 8) provides insight regarding the 
role of each kinase as an inhibitor target in TF-1/FLT3-ITD cells. For example, TAE-684 and 
HG7-92-01 both potently inhibited the growth of TF-1/FLT3-ITD cells, with IC50 values of 160 
and 59 nM, respectively. These values are lower than the individual IC50 values obtained for 
either kinase in vitro (see Table 8), suggesting that dual inhibition of both FES and FLT3-ITD 
may be responsible for their potent growth inhibitory effects.  On the other hand, WZ4-49-1 and 
WZ4-49-8 block TF-1/FLT3-ITD cell growth with IC50 values of 465 and 816 nM, respectively, 
values almost identical to those observed with FES in vitro (494 and 706 nM respectively).  In 
contrast, these two compounds are much less potent against FLT3-ITD in vitro (1390 and 14345 
nM, respectively). Taken together, these results suggest that suppression of TF-1/FLT3-ITD cell 
growth by these two pyrazolopyrimidines is the result of selective FES inhibition. Finally, 
tandutinib inhibited TF-1/FLT3-ITD cell growth and FLT3-ITD kinase activity in vitro with very 
similar potencies (825 vs. 788 nM, respectively), suggesting that tandutinib works primarily via 
FLT3-ITD.  Note that tandutinib had no effect on FES kinase activity in vitro, even at 
concentrations as high as 100 µM. In a final series of experiments, we explored the sensitivity of 
TF-1 cells transformed with the FLT3 kinase domain point mutant D835Y, in which FES activity 
is not enhanced.  In these cells, TAE-684 treatment resulted in potent growth suppression, with 
an IC50 value close to 150 nM (Figure 16).  This value is virtually identical to that obtained with 
the TF-1/FLT3-ITD cells, suggesting that the cellular activity of TAE-684 may result primarily 
from inhibition of the FLT3 mutants.  HG7-92-01, on the other hand, had very little activity 
against TF-1/FLT3-D835Y cells, which is consistent with the reduced sensitivity of this 
compound to FLT3-D835Y in vitro in comparison to FLT3-ITD (Table 8).  This observation,   
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Figure 16: Inhibitor sensitivity of TF-1 cells transformed with wild-type (WT) and AML-associated 
mutants of FLT3. 
TF-1 cells expressing WT, ITD, and D835Y forms of FLT3 were incubated with the kinase inhibitors shown over a 
range of concentrations for 72 hours. Cell viability was determined using the Cell Titer Blue Assay for triplicate 
cultures at each drug concentration.  Raw fluorescence data were corrected for background and then normalized to 
cultures grown in the presence of the DMSO carrier solvent alone (0.1%). Results are presented as the mean 
normalized growth ± S.D.  Curves were fit by non-linear regression analysis to estimate the IC50 values shown; blue, 
TF-1/FLT3-ITD cells; green, TF-1/FLT3-D835Y cells. 
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plus the finding that FLT3-D835Y is unable to activate FES as a secondary inhibitor target, 
likely explains its lack of activity in TF-1/FLT3-D835Y cells.  Both of the pyrazolopyrimidines, 
WZ4-49-1 and WZ4-49-8, inhibited TF-1/FLT3-D835Y cell growth with IC50 values of 597 and 
1312 nM, respectively.  Interestingly, in vitro kinase assays show that the D835Y mutation 
sensitizes FLT3 to inhibition by both of these compounds relative to FLT3-ITD, suggesting that 
these compounds directly inhibit FLT3-D835Y in cells. 
A.3 DISCUSSION 
Previous studies have shown the FES tyrosine kinase is constitutively active in FLT3-ITD+ AML 
cells, and that RNAi knockdown of FES expression causes growth arrest and apoptosis.  In the 
present study, we tested the efficacy small molecule inhibitors of FES kinase activity against 
FLT3-ITD+ AML cells. Our results show that direct inhibition of FES kinase activity by two 
selective pyrazolopyrimidine compounds resulted in growth suppression in MV4-11 cells, which 
are derived from a FLT3-ITD+ patient, and in TF-1 myeloid cells transformed by retroviral 
transduction of FLT3-ITD.  Furthermore, inhibitors with activity against both FES and FLT3-
ITD kinases in vitro blocked FLT3-ITD+ AML cell growth in the low nanomolar range, 
suggesting that dual inhibition of this key AML driver mutation and the proximal effector kinase 
FES provides added benefit in this type of AML.  Indeed, these dual inhibitors, TAE-684 and 
HG7-92-01, were about 8- and 20-fold more potent than tandutinib, which inhibits FLT3-ITD 
but not FES. 
One unexpected discovery from our study was the observation that the AML-associated 
FLT3 point mutant, D835Y, did not activate FES in TF-1 cells transformed with this mutant.  
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This observation is consistent with earlier work showing important differences in the 
downstream kinases and signaling pathways activated by FLT3-ITD vs. FLT3-D835Y.  For 
example, SRC kinase is activated by FLT3-ITD but not by FLT3-D835Y in 32D/FLT3-ITD 
expressing cells (288). Furthermore, siRNA knockdown of SRC eliminated STAT5 activity in 
these cells.  Treatment with the SFK inhibitor, dasatinib, reduced STAT5 activation in MV4-11 
cells and reduced the growth of primary AML patient samples. Additionally, FLT3-ITD 
signaling suppresses the expression of two transcription factors essential for myeloid cell 
differentiation, while the D835Y does not (278).  The mechanism of this suppression is unknown 
but RNA levels are suppressed in FLT3-ITD expressing cells. These differences in signaling may 
help to explain increased disease severity observed in FLT3-ITD vs. FLT3-D835Y knock-in 
mouse models and by extension the worse prognosis for patients with FLT3-ITD vs. D835Y 
(289).   
Consideration of differences in pyrazolopyrimidine inhibitor potency between the two 
model systems used in our study (MV4-11 vs. TF-1/FLT3-ITD cells) provides some additional 
mechanistic insight regarding inhibitor target kinase selection in vivo. For example, the potency 
of both pyrazolopyrimidines, WZ4-49-1 and WZ4-49-8, was about two-fold higher in TF-
1/FLT3-ITD cells compared to MV4-11 cells.  One possible explanation for this difference is 
that in MV4-11 cells, FLT3-ITD activates not only FES, but also SYK and several myeloid 
members of the Src kinase family (HCK, LYN, and FGR). Activation of these alternative kinase 
pathways may help to overcome the effect of FES inhibition, resulting in reduced sensitivity to 
the inhibitor. Note that previous KINOMEscan data showed that WZ4-49-8 does not bind to 
HCK, LYN or SYK (481) strongly suggesting that its growth suppressive activities in MV4-11 
cells are primarily due to inhibition of FES and not these other AML-associated kinases.  The 
 121 
kinase target specificity profile of the structurally related compound, WZ4-49-1, is likely to be 
quite similar.  On the other hand, TF-1/FLT3-ITD cells do not express HCK, LYN or FGR (data 
not shown), potentially making FLT3-ITD oncogenic signaling more dependent on FES and thus 
more sensitive to these FES-selective inhibitors. 
Our study also revealed an unexpected sensitizing effect of the FLT3-D835Y mutation 
towards the two pyrazolopyrimidine inhibitors. In vitro kinase assays showed that FLT3-D835Y 
was about 5-fold more sensitive to both WZ4-49-1 and WZ4-49-8 compared to wild-type FLT3.  
This result is consistent with previous KINOMEscan analysis of WZ4-49-8 target specificity, in 
which no displacement activity was observed with the wild-type or ITD form of FLT3, while the 
D835Y and D835H both showed partial responses (481).  This observation is consistent with 
their growth suppressive activities in TF-1/FLT3-D835Y cells, where these compounds inhibit 
cell proliferation with IC50 values that closely mirror their potency against the FLT3-D835Y 
kinase domain in vitro.  In contrast, the D835Y mutation results in strong resistance to tandutinib 
in vitro, and this compound had no effect on TF-1/FLT3-D835Y cell proliferation. 
In summary, these studies provide the first evidence that ATP-site inhibitors with 
selectivity for FES kinase activity cause growth arrest and induce apoptosis in AML cells.  These 
results validate FES as a viable inhibitor target for drug development in AML.  Furthermore, 
compounds with dual activity against both FES and FLT3-ITD induce very strong apoptotic 
responses in FLT3-ITD+ AML cells, suggesting that this therapeutic approach may be valuable 
in primary FLT3-ITD+ AML as well. 
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